-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Hm0AwpyurKnPQpbJ4Gh/ov4F5Gm9g11l3pvUQT3scGkLHIrSbbRo9+y2rmCPapw4
 rdlBXiuZAaPEczfKbVW8Cg==

<SEC-DOCUMENT>0000014272-01-500024.txt : 20020425
<SEC-HEADER>0000014272-01-500024.hdr.sgml : 20020425
ACCESSION NUMBER:		0000014272-01-500024
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20010930
FILED AS OF DATE:		20011114
DATE AS OF CHANGE:		20011203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRISTOL MYERS SQUIBB CO
		CENTRAL INDEX KEY:			0000014272
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				220790350
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01136
		FILM NUMBER:		1792093

	BUSINESS ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154
		BUSINESS PHONE:		2125464000

	MAIL ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BRISTOL MYERS CO
		DATE OF NAME CHANGE:	19891012
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bmssept.htm
<DESCRIPTION>BMS 10 Q
<TEXT>
<!doctype html public "-//w3c//dtd html 4.0 transitional//en">
<html>
<head>

   <meta name="GENERATOR" content="Mozilla/4.72 [en]C-BMY  (WinNT; U) [Netscape]">
</head>
<body bgcolor="#FFFFFF" link="#0000FF" vlink="#800080">
<center>
  <a NAME="_Toc514233754"></a><b><font face="CG Times" size="+2">SECURITIES AND
  EXCHANGE COMMISSION</font></b>
  <p><font face="CG Times">WASHINGTON, D.C. 20549</font> <br>
    &nbsp; <br>
    &nbsp;
  <p><a NAME="_Toc514233755"></a><b><font face="CG Times" size="+2">FORM 10-Q</font></b>
    <br>
    &nbsp; <br>
    &nbsp;
  <p><font face="CG Times">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
    THE</font>
  <p><font face="CG Times">SECURITIES EXCHANGE ACT OF 1934</font> <br>
    &nbsp; <br>
    &nbsp;
  <p><a NAME="_Toc514233756"></a><b><font face="CG Times" size="+2">FOR THE QUARTERLY
    PERIOD ENDED SEPTEMBER 30, 2001</font></b> <br>
    &nbsp; <br>
    &nbsp;
  <p><font face="CG Times">Commission File Number 1-1136</font> <br>
    &nbsp; <br>
    &nbsp;
  <p><a NAME="_Toc514233757"></a><b><font face="CG Times" size="+2">BRISTOL-MYERS
    SQUIBB COMPANY</font></b>
  <p><font face="CG Times">(Exact name of registrant as specified in its charter)</font>
</center>
<p><br>
  <br>
  &nbsp; <br>
  &nbsp; <br>
  &nbsp; <br>
  &nbsp;
<table BORDER=0 CELLSPACING=0 CELLPADDING=7 WIDTH="655" >
  <tr>
    <td VALIGN=TOP WIDTH="56%">
      <center>
        <b><font face="CG Times">Delaware</font></b>
      </center>
    </td>
    <td VALIGN=TOP WIDTH="44%">
      <center>
        <b><font face="CG Times">22-079-0350</font></b>
      </center>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="56%">
      <center>
        <font face="CG Times">(State or other jurisdiction of</font>
        <p><font face="CG Times">incorporation or organization)</font>
      </center>
    </td>
    <td VALIGN=TOP WIDTH="44%">
      <center>
        <font face="CG Times">(IRS Employer Identification No.)</font>
      </center>
    </td>
  </tr>
</table>
<br>
&nbsp; <br>
&nbsp; <br>
&nbsp;
<center>
  <p><font face="CG Times">345 Park Avenue, New York, N.Y. 10154</font>
  <p><font face="CG Times">(Address of principal executive offices)</font>
  <p><font face="CG Times">Telephone: (212) 546-4000</font>
</center>
<p><br>
  <br>
  <br>
<p><b><font face="CG Times">Indicate by check mark whether the registrant (1)
  has filed all reports required to be filed by Section 13 or 15(d) of the Securities
  Exchange Act of 1934 during the preceding 12 months (or for such shorter period
  that the registrant was required to file such reports), and (2) has been subject
  to such filing requirements for the past 90 days.</font></b>
<p><b><font face="CG Times">Yes [ X ] No [ ]</font></b>
<p><font face="CG Times">At Ocotber 31, 2001, there were 1,934,856,629 shares
  outstanding of the Registrant's $.10 par value Common Stock.</font>
<hr>
<br>
&nbsp;
<table BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="75%" >
  <tr>
    <td>
      <center>
        <font color="#333333" size="+1">BRISTOL-MYERS SQUIBB COMPANY&nbsp;</font>
      </center>
    </td>
  </tr>
  <tr>
    <td>
      <center>
        <font color="#333333" size="+1">INDEX TO FORM 10-Q</font>
      </center>
    </td>
  </tr>
  <tr>
    <td>
      <center>
        <font color="#333333" size="+1">September 30, 2001&nbsp;</font>
      </center>
    </td>
  </tr>
</table>
<p><b>PART I - Financial Information</b>
<dir><b>Item 1.</b>
  <p>Financial Statements (Unaudited):
  <blockquote><a href="#_Toc514474292">Consolidated Balance Sheet - September
    30, 2001 and December 31, 2000</a>
    <p><a href="#_Toc514474296">Consolidated Statement of Earning and Comprehensive
      Income for the nine months ended September 30, 2001 and 2000</a>
    <p><a href="#_Toc514474297">Consolidated Statement of Cash Flows </a><a href="#_Toc514474296">for
      the nine months ended September 30, 2001 and 2000</a>
    <p><a href="#_Toc514474298">Notes to Condensed Consolidated Financial Statements</a>
    <p><a href="#_Toc514474299">Report of Independent Accountants</a>
  </blockquote>
  <b>Item 2.</b>
  <blockquote><a href="#_Toc514474303">Management's Discussion and Analysis of
    Financial Condition and Results of Operations</a></blockquote>
</dir>
<b>PART II - OTHER INFORMATION</b>
<dir><b>Item 1.</b>
  <blockquote><a href="#_Toc514474305">Legal Proceedings</a></blockquote>
  <b>Item 6.</b>
  <blockquote><a href="#_Toc514474307">Exhibits and Reports on Form 8-K</a></blockquote>
  <b><a href="#_Toc514474308">Signatures</a></b> <br>
  &nbsp;
  <p>
  <hr>
  <br>
  <br>
  &nbsp;</dir>
<a NAME="_Toc514233758"></a><a NAME="_Toc514474290"></a><b><u><font face="CG Times" size="+1">PART
I - FINANCIAL INFORMATION</font></u></b>
<p><a NAME="_Toc514233759"></a><a NAME="_Toc514474291"></a><u><font face="CG Times" size="+1">Item
  1. Financial Statements</font></u> <br>
  &nbsp; <br>
  &nbsp; <br>
  &nbsp; <br>
  &nbsp; <br>
  &nbsp;
<table BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="817" BGCOLOR="#FFFFFF" 0 bordercolor="#FFFFFF" >
  <tr BGCOLOR="#FFFFFF">
    <td VALIGN=TOP COLSPAN="4" HEIGHT="16" BGCOLOR="#FFFFFF" bordercolor="#FFFFFF">
      <center>
        <b><font face="CG Times" size="+1">BRISTOL-MYERS SQUIBB COMPANY</font></b>
      </center>
    </td>
  </tr>
  <tr BGCOLOR="#FFFFFF">
    <td VALIGN=TOP COLSPAN="4" HEIGHT="16" BGCOLOR="#FFFFFF" bordercolor="#FFFFFF">
      <center>
        <a NAME="_Toc514233760"></a><a NAME="_Toc514233760"></a><a NAME="_Toc514233760"></a><a NAME="_Toc514474292"></a><b><font face="CG Times" size="+1">CONSOLIDATED
        BALANCE SHEET - ASSETS</font></b>
      </center>
    </td>
  </tr>
  <tr BGCOLOR="#FFFFFF">
    <td VALIGN=TOP COLSPAN="4" HEIGHT="16" BGCOLOR="#FFFFFF" bordercolor="#FFFFFF">
      <center>
        <b><font face="CG Times">(Unaudited, dollars in millions)</font></b>
      </center>
    </td>
  </tr>
</table>
<table BGCOLOR="#FFFFFF" 0 bordercolor="#FFFFFF" bordercolorlight="#FFFFFF" bordercolordark="#FFFFFF" >
  <tr>
    <td VALIGN=TOP WIDTH="474" height="20">&nbsp;</td>
    <td VALIGN=TOP WIDTH="165" height="20">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">September
        30,</font></div>
    </td>
    <td VALIGN=TOP WIDTH="164" height="20">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">December
        31, </font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="474">&nbsp;</td>
    <td valign=TOP bgcolor="#FFFFFF" bordercolor="#FFFFFF" width="165">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif">2001</font></u></div>
    </td>
    <td valign=TOP bgcolor="#FFFFFF" bordercolor="#FFFFFF" width="164">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif">2000</font></u></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474"><font face="Arial, Helvetica, sans-serif">Current
      Assets:</font></td>
    <td VALIGN=TOP BGCOLOR="#FFFFFF" bordercolor="#FFFFFF" WIDTH="165">&nbsp;</td>
    <td VALIGN=TOP BGCOLOR="#FFFFFF" bordercolor="#FFFFFF" WIDTH="164">&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474">
      <dir><font face="Arial, Helvetica, sans-serif">Cash and cash equivalents</font></dir>
    </td>
    <td VALIGN=bottom WIDTH="165">
      <div align=right><font face="Arial, Helvetica, sans-serif">$2,801</font></div>
    </td>
    <td VALIGN=bottom WIDTH="164">
      <div align=right><font face="Arial, Helvetica, sans-serif">$3,182</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474">
      <dir><font face="Arial, Helvetica, sans-serif">Time deposits and marketable
        securities</font></dir>
    </td>
    <td VALIGN=bottom WIDTH="165">
      <div align=right><font face="Arial, Helvetica, sans-serif">279</font></div>
    </td>
    <td VALIGN=bottom WIDTH="164">
      <div align=right><font face="Arial, Helvetica, sans-serif">203</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474">
      <dir><font face="Arial, Helvetica, sans-serif">Receivables, net of allowances</font></dir>
    </td>
    <td VALIGN=bottom WIDTH="165">
      <div align=right><font face="Arial, Helvetica, sans-serif">3,738</font></div>
    </td>
    <td VALIGN=bottom WIDTH="164">
      <div align=right><font face="Arial, Helvetica, sans-serif">3,662</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474">&nbsp;</td>
    <td VALIGN=TOP WIDTH="165">&nbsp;</td>
    <td VALIGN=TOP WIDTH="164">&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474">
      <dir><font face="Arial, Helvetica, sans-serif">Finished goods</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="165">
      <div align=right><font face="Arial, Helvetica, sans-serif">1,078</font></div>
    </td>
    <td VALIGN=TOP WIDTH="164">
      <div align=right><font face="Arial, Helvetica, sans-serif">890</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474">
      <dir><font face="Arial, Helvetica, sans-serif">Work in process</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="165">
      <div align=right><font face="Arial, Helvetica, sans-serif">383</font></div>
    </td>
    <td VALIGN=TOP WIDTH="164">
      <div align=right><font face="Arial, Helvetica, sans-serif">473</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474">
      <dir><font face="Arial, Helvetica, sans-serif">Raw and packaging materials</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="165">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>209</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="164">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>468</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474">
      <dir><font face="Arial, Helvetica, sans-serif">Inventories</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="165">
      <div align=right><font face="Arial, Helvetica, sans-serif">1,670</font></div>
    </td>
    <td VALIGN=TOP WIDTH="164">
      <div align=right><font face="Arial, Helvetica, sans-serif">1,831</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474">&nbsp;</td>
    <td VALIGN=TOP WIDTH="165">&nbsp;</td>
    <td VALIGN=TOP WIDTH="164">&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474">
      <dir><font face="Arial, Helvetica, sans-serif">Prepaid expenses</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="165">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>985</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="164">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>946</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474">&nbsp;</td>
    <td VALIGN=TOP WIDTH="165">&nbsp;</td>
    <td VALIGN=TOP WIDTH="164">&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474">
      <dir><font face="Arial, Helvetica, sans-serif">Total Current Assets</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="165">
      <div align=right><font face="Arial, Helvetica, sans-serif">9,473</font></div>
    </td>
    <td VALIGN=TOP WIDTH="164">
      <div align=right><font face="Arial, Helvetica, sans-serif">9,824</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474">&nbsp;</td>
    <td VALIGN=TOP WIDTH="165">&nbsp;</td>
    <td VALIGN=TOP WIDTH="164">&nbsp;</td>
  </tr>
  <tr>
    <td valign=TOP width="474">&nbsp;</td>
    <td valign=TOP width="165">&nbsp;</td>
    <td valign=TOP width="164">&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474"><font face="Arial, Helvetica, sans-serif">Property,
      Plant and Equipment</font></td>
    <td VALIGN=TOP WIDTH="165">
      <div align=right><font face="Arial, Helvetica, sans-serif">7,953</font></div>
    </td>
    <td VALIGN=TOP WIDTH="164">
      <div align=right><font face="Arial, Helvetica, sans-serif">7,926</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474"><font face="Arial, Helvetica, sans-serif">Less:
      Accumulated depreciation</font></td>
    <td VALIGN=bottom WIDTH="165">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>3,268</u></font></div>
    </td>
    <td VALIGN=bottom WIDTH="164">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>3,378</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474">&nbsp;</td>
    <td VALIGN=TOP WIDTH="165">
      <div align=right><font face="Arial, Helvetica, sans-serif">4,685</font></div>
    </td>
    <td VALIGN=TOP WIDTH="164">
      <div align=right><font face="Arial, Helvetica, sans-serif">4,548</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="474"><font face="Arial, Helvetica, sans-serif">Excess
      of cost over net tangible assets arising from business acquisisitions</font></td>
    <td valign=bottom width="165">
      <div align=right><font face="Arial, Helvetica, sans-serif">1,377</font></div>
    </td>
    <td valign=bottom width="164">
      <div align=right><font face="Arial, Helvetica, sans-serif">1,436</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474"><font face="Arial, Helvetica, sans-serif">Cash
      Held for Acquisition of DuPont Pharmaceuticals Long-Term Assets (See Note
      8) </font></td>
    <td VALIGN=bottom WIDTH="165">
      <div align=right><font face="Arial, Helvetica, sans-serif">7,156</font></div>
    </td>
    <td VALIGN=bottom WIDTH="164">
      <div align=right><font face="Arial, Helvetica, sans-serif">-</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474"><font face="Arial, Helvetica, sans-serif">Other
      Assets</font></td>
    <td VALIGN=TOP WIDTH="165">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>1,944</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="164">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>1,770</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="474">&nbsp;</td>
    <td valign=TOP width="165">&nbsp;</td>
    <td valign=TOP width="164">&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="474">
      <dir>
        <dir><font face="Arial, Helvetica, sans-serif">Total Assets</font></dir>
      </dir>
    </td>
    <td VALIGN=TOP WIDTH="165">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>$24,635</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="164">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>$17,578</u></font></div>
    </td>
  </tr>
</table>
<blockquote>
  <p><br>
    &nbsp; </p>
  <p><font face="CG Times" size="+0">The accompanying notes are an integral part
    of these financial statements.</font> <br>
    &nbsp; </p>
  <p>&nbsp; </p>
  <hr>
  <br>
  &nbsp; <br>
  &nbsp; <br>
  &nbsp; <br>
  &nbsp; <br>
  &nbsp; <br>
  &nbsp; </blockquote>
<table BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="668" HEIGHT="734" BGCOLOR="#FFFFFF" bordercolorlight="#FFFFFF" bordercolordark="#FFFFFF" bordercolor="#FFFFFF" >
  <tr BGCOLOR="#FFFFFF">
    <td VALIGN=TOP COLSPAN="3" HEIGHT="22">
      <center>
        <b><font face="CG Times" size="+1">BRISTOL-MYERS SQUIBB COMPANY</font></b>
      </center>
    </td>
  </tr>
  <tr BGCOLOR="#FFFFFF">
    <td VALIGN=TOP COLSPAN="3" HEIGHT="35">
      <center>
        <b><font face="CG Times" size="+1">CONSOLIDATED BALANCE SHEET -</font></b>
        <br>
        <b><font face="CG Times" size="+1">LIABILITIES AND STOCKHOLDERS' EQUITY</font></b>
        <p><b><font face="CG Times" size="+1">(Unaudited, dollars in millions)</font></b>
      </center>
      <p><br>
      <center>

          <tr>
            <td VALIGN=TOP WIDTH="63%" HEIGHT="31">&nbsp;</td>
            <td VALIGN=TOP WIDTH="15%" BGCOLOR="#FFFFFF" bordercolor="#FFFFFF" bordercolordark="#FFFFFF" bordercolorlight="#FFFFFF" height="31">
              <div align="right"><font face="Arial, Helvetica, sans-serif">September
                30, </font></div>
            </td>
            <td VALIGN=TOP WIDTH="22%" BGCOLOR="#FFFFFF" bordercolor="#FFFFFF" bordercolordark="#FFFFFF" bordercolorlight="#FFFFFF" height="31">
              <div align="right"><font face="Arial, Helvetica, sans-serif">December
                31, </font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%" HEIGHT="12">&nbsp;</td>
            <td VALIGN=TOP WIDTH="15%" BGCOLOR="#FFFFFF" bordercolor="#FFFFFF" bordercolordark="#FFFFFF" bordercolorlight="#FFFFFF" height="12">
              <div align="right"><u><font face="Arial, Helvetica, sans-serif" size="+0">2001</font></u></div>
            </td>
            <td VALIGN=TOP WIDTH="22%" BGCOLOR="#FFFFFF" bordercolor="#FFFFFF" bordercolordark="#FFFFFF" bordercolorlight="#FFFFFF" height="12">
              <div align="right"><u><font face="Arial, Helvetica, sans-serif" size="+0">2000</font></u></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%" height="20"><font face="Arial, Helvetica, sans-serif">Current
              Liabilities:</font></td>
            <td VALIGN=TOP WIDTH="15%" height="20">&nbsp;</td>
            <td VALIGN=TOP WIDTH="22%" height="20">&nbsp;</td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%">
              <dir><font face="Arial, Helvetica, sans-serif">Short-term borrowings
                (see Note 7)</font></dir>
            </td>
            <td VALIGN=TOP WIDTH="15%">
              <dir>
                <dir>
                  <div align=right><font face="Arial, Helvetica, sans-serif">$1,734</font></div>
                </dir>
              </dir>
            </td>
            <td VALIGN=TOP WIDTH="22%">
              <div align=right><font face="Arial, Helvetica, sans-serif">$162</font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%">
              <dir><font face="Arial, Helvetica, sans-serif">Accounts payable</font></dir>
            </td>
            <td VALIGN=TOP WIDTH="15%">
              <dir>
                <dir>
                  <div align=right><font face="Arial, Helvetica, sans-serif">1,432</font></div>
                </dir>
              </dir>
            </td>
            <td VALIGN=TOP WIDTH="22%">
              <div align=right><font face="Arial, Helvetica, sans-serif">1,702</font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%">
              <dir><font face="Arial, Helvetica, sans-serif">Accrued expenses
                and other current liabilities</font></dir>
            </td>
            <td VALIGN=TOP WIDTH="15%">
              <dir>
                <dir>
                  <div align=right><font face="Arial, Helvetica, sans-serif">2,809</font></div>
                </dir>
              </dir>
            </td>
            <td VALIGN=TOP WIDTH="22%">
              <div align=right><font face="Arial, Helvetica, sans-serif">3,067</font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%" HEIGHT="21">
              <dir><font face="Arial, Helvetica, sans-serif">U.S. and foreign
                income taxes payable</font></dir>
            </td>
            <td VALIGN=TOP WIDTH="15%" HEIGHT="21">
              <dir>
                <dir>
                  <div align=right><font face="Arial, Helvetica, sans-serif"><u>1,072</u></font></div>
                </dir>
              </dir>
            </td>
            <td VALIGN=TOP WIDTH="22%" HEIGHT="21">
              <div align=right><font face="Arial, Helvetica, sans-serif"><u>701</u></font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%" HEIGHT="21"><font face="Arial, Helvetica, sans-serif">Total
              Current Liabilities</font></td>
            <td VALIGN=TOP WIDTH="15%" HEIGHT="21">
              <div align=right><font face="Arial, Helvetica, sans-serif">7,047</font></div>
            </td>
            <td VALIGN=TOP WIDTH="22%" HEIGHT="21">
              <div align=right><font face="Arial, Helvetica, sans-serif">5,632</font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%" HEIGHT="16">&nbsp;</td>
            <td VALIGN=TOP WIDTH="15%" HEIGHT="16">&nbsp;</td>
            <td VALIGN=TOP WIDTH="22%" HEIGHT="16">&nbsp;</td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%" HEIGHT="21"><font face="Arial, Helvetica, sans-serif">Other
              Liabilities</font></td>
            <td VALIGN=TOP WIDTH="15%" HEIGHT="21">
              <div align=right><font face="Arial, Helvetica, sans-serif">1,394</font></div>
            </td>
            <td VALIGN=TOP WIDTH="22%" HEIGHT="21">
              <div align=right><font face="Arial, Helvetica, sans-serif">1,430</font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%" HEIGHT="21"><font face="Arial, Helvetica, sans-serif">Long-Term
              Debt (see Note 7)</font></td>
            <td VALIGN=TOP WIDTH="15%" HEIGHT="21">
              <div align=right><font face="Arial, Helvetica, sans-serif"><u>6,259</u></font></div>
            </td>
            <td VALIGN=TOP WIDTH="22%" HEIGHT="21">
              <div align=right><font face="Arial, Helvetica, sans-serif"><u>1,336</u></font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%">
              <dir><font face="Arial, Helvetica, sans-serif">Total Liabilities</font></dir>
            </td>
            <td VALIGN=TOP WIDTH="15%">
              <dir>
                <dir>
                  <div align=right><font face="Arial, Helvetica, sans-serif"><u>14,700</u></font></div>
                </dir>
              </dir>
            </td>
            <td VALIGN=TOP WIDTH="22%">
              <div align=right><font face="Arial, Helvetica, sans-serif"><u>8,398</u></font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%"><font face="Arial, Helvetica, sans-serif">Stockholders'
              Equity:</font></td>
            <td VALIGN=TOP WIDTH="15%">&nbsp;</td>
            <td VALIGN=TOP WIDTH="22%">&nbsp;</td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%">
              <dir><font face="Arial, Helvetica, sans-serif">Preferred stock,
                $2 convertible series:</font>
                <dir><font face="Arial, Helvetica, sans-serif">Authorized 10 million
                  shares; issued and outstanding 8,952 in 2001 and 9,864 in 2000,
                  liquidation value of $50 per share</font></dir>
              </dir>
            </td>
            <td VALIGN=bottom WIDTH="15%">
              <div align=right><font face="Arial, Helvetica, sans-serif">-</font></div>
            </td>
            <td VALIGN=bottom WIDTH="22%">
              <div align=right><font face="Arial, Helvetica, sans-serif">-</font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%">
              <dir><font face="Arial, Helvetica, sans-serif">Common stock, par
                value of $.10 per share:</font>
                <dir><font face="Arial, Helvetica, sans-serif">Authorized 4.5
                  billion shares; issued 2,199,549,703 in 2001 and 2,197,900,835
                  in 2000</font></dir>
              </dir>
            </td>
            <td VALIGN=bottom WIDTH="15%">
              <div align=right><font face="Arial, Helvetica, sans-serif">220</font></div>
            </td>
            <td VALIGN=bottom WIDTH="22%">
              <div align=right><font face="Arial, Helvetica, sans-serif">220</font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%">
              <dir><font face="Arial, Helvetica, sans-serif">Capital in excess
                of par value of stock</font></dir>
            </td>
            <td VALIGN=bottom WIDTH="15%">
              <div align=right><font face="Arial, Helvetica, sans-serif">2,272</font></div>
            </td>
            <td VALIGN=bottom WIDTH="22%">
              <div align=right><font face="Arial, Helvetica, sans-serif">2,002</font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%">
              <dir><font face="Arial, Helvetica, sans-serif">Other comprehensive
                income</font></dir>
            </td>
            <td VALIGN=bottom WIDTH="15%">
              <div align=right><font face="Arial, Helvetica, sans-serif">(1,127)</font></div>
            </td>
            <td VALIGN=bottom WIDTH="22%">
              <div align=right><font face="Arial, Helvetica, sans-serif">(1,103)</font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%" HEIGHT="21">
              <dir><font face="Arial, Helvetica, sans-serif">Retained earnings</font></dir>
            </td>
            <td VALIGN=bottom WIDTH="15%" HEIGHT="21">
              <div align=right><font face="Arial, Helvetica, sans-serif"><u>19,756</u></font></div>
            </td>
            <td VALIGN=bottom WIDTH="22%" HEIGHT="21">
              <div align=right><font face="Arial, Helvetica, sans-serif"><u>17,781</u></font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%" HEIGHT="21">&nbsp;</td>
            <td VALIGN=bottom WIDTH="15%" HEIGHT="21">
              <div align=right><font face="Arial, Helvetica, sans-serif">21,121</font></div>
            </td>
            <td VALIGN=bottom WIDTH="22%" HEIGHT="21">
              <div align=right><font face="Arial, Helvetica, sans-serif">18,900</font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%">
              <dir><font face="Arial, Helvetica, sans-serif">Less cost of treasury
                stock - 262,535,055 common shares in 2001 and 244,365,726 in 2000</font></dir>
            </td>
            <td VALIGN=bottom WIDTH="15%">
              <div align=right><font face="Arial, Helvetica, sans-serif"><u>11,186</u></font></div>
            </td>
            <td VALIGN=bottom WIDTH="22%">
              <div align=right><font face="Arial, Helvetica, sans-serif"><u>9,720</u></font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%">
              <dir>
                <dir><font face="Arial, Helvetica, sans-serif">Total Stockholders'
                  Equity</font></dir>
              </dir>
            </td>
            <td VALIGN=TOP WIDTH="15%">
              <dir>
                <dir>
                  <div align=right><font face="Arial, Helvetica, sans-serif"><u>9,935</u></font></div>
                </dir>
              </dir>
            </td>
            <td VALIGN=TOP WIDTH="22%">
              <div align=right><font face="Arial, Helvetica, sans-serif"><u>9,180</u></font></div>
            </td>
          </tr>
          <tr>
            <td VALIGN=TOP WIDTH="63%" HEIGHT="53">
              <dir><font face="Arial, Helvetica, sans-serif">Total Liabilities
                and Stockholders' Equity</font></dir>
            </td>
            <td VALIGN=TOP WIDTH="15%" HEIGHT="53">
              <div align=right><font face="Arial, Helvetica, sans-serif"><u>$24,635</u></font></div>
            </td>
            <td VALIGN=TOP WIDTH="22%" HEIGHT="53">
              <div align=right><font face="Arial, Helvetica, sans-serif"><u>$17,578</u></font></div>
            </td>
          </tr>
        </table>
      </center>
    </td>
  </tr>
  <tr BGCOLOR="#FFFFFF">
    <td VALIGN=TOP COLSPAN="3" HEIGHT="16">&nbsp;</td>
  </tr>
</table>
<blockquote>
  <p><font face="CG Times" size="+0">The accompanying notes are an integral part
    of these financial statements.</font> <br>
    &nbsp; </p>
  <p>&nbsp; </p>
  <hr>
  <br>
  &nbsp; <br>
  &nbsp; <br>
  &nbsp; <br>
  &nbsp; <br>
  &nbsp; <br>
  &nbsp; </blockquote>
<table BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="685" >
  <tr BGCOLOR="#FFFFFF" bordercolor="#FFFFFF">
    <td VALIGN=TOP COLSPAN="3" HEIGHT="16"><a NAME="_Toc514233764"></a><a NAME="_Toc514233764"></a><a NAME="_Toc514233764"></a><a NAME="_Toc514233764"></a><a NAME="_Toc514233764"></a><a NAME="_Toc514474295"></a>
      <center>
        <b><font face="CG Times" size="+1">BRISTOL-MYERS SQUIBB COMPANY</font></b>
      </center>
    </td>
  </tr>
  <tr BGCOLOR="#FFFFFF" bordercolor="#FFFFFF">
    <td VALIGN=TOP COLSPAN="3" HEIGHT="16"><a NAME="_Toc514233764"></a><a NAME="_Toc514233764"></a><a NAME="_Toc514233764"></a><a NAME="_Toc514233764"></a><a NAME="_Toc514233764"></a><a NAME="_Toc514474295"></a>
      <center>
        <b><font face="CG Times" size="+1">CONSOLIDATED STATEMENT OF EARNINGS</font></b>
      </center>
    </td>
  </tr>
  <tr BGCOLOR="#FFFFFF" bordercolor="#FFFFFF">
    <td VALIGN=TOP COLSPAN="3" HEIGHT="16">
      <center>
        <a NAME="_Toc514233765"></a><a NAME="_Toc514233765"></a><a NAME="_Toc514233765"></a><a NAME="_Toc514234389"></a><a NAME="_Toc514474296"></a><b><font face="CG Times" size="+1">AND
        COMPREHENSIVE INCOME</font></b>
      </center>
    </td>
  </tr>
  <tr BGCOLOR="#FFFFFF" bordercolor="#FFFFFF">
    <td VALIGN=TOP COLSPAN="3" HEIGHT="16">
      <center>
        <b><font face="CG Times">(Unaudited, in millions except per share amounts)</font></b>
      </center>
    </td>
  </tr>
  <tr BGCOLOR="#FFFFFF" bordercolor="#FFFFFF">
    <td VALIGN=TOP WIDTH="64%" HEIGHT="24">&nbsp;</td>
    <td VALIGN=TOP COLSPAN="2" HEIGHT="24">&nbsp;</td>
  </tr>
</table>
<table BORDER=0 CELLSPACING=1 CELLPADDING=1 WIDTH="684" >
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="18">&nbsp;</td>
    <td COLSPAN="2" HEIGHT="18">
      <center>
        <font face="Arial, Helvetica, sans-serif"> Three Months Ended <u>September
        30,</u> </font>
      </center>
    </td>
    <td VALIGN=TOP COLSPAN="2" HEIGHT="18">
      <center>
        <font face="Arial, Helvetica, sans-serif"> Nine Months Ended <u>September
        30,</u> </font>
      </center>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="16">&nbsp;</td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="16">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>2001&nbsp;</u></font></div>
    </td>
    <td valign=TOP width="13%" height="18">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>2000&nbsp;</u></font></div>
    </td>
    <td valign=TOP width="12%" height="18">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>2001&nbsp;</u></font></div>
    </td>
    <td valign=TOP width="13%" height="18">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>2000&nbsp;</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="18"><font face="Arial, Helvetica, sans-serif" size="+0"><u>EARNINGS</u></font></td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="18">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="18">&nbsp;</td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="18">&nbsp;</td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="18">&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="34"><font face="Arial, Helvetica, sans-serif" size="+0">Net
      Sales</font></td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="34">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>$4,743</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="34">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>$4,563</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="34">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>$14,141</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="34">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>$13,432&nbsp;</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="16"><font face="Arial, Helvetica, sans-serif" size="+0">Expenses:</font></td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="16">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="16">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="17">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Cost of products
        sold</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,331&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,200</font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">3,961&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">3,471&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="17">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Marketing, selling,
        administrative and other</font></dir>
    </td>
    <td VALIGN=bottom WIDTH="11%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">939&nbsp;</font></div>
    </td>
    <td VALIGN=bottom WIDTH="13%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,001</font></div>
    </td>
    <td VALIGN=bottom WIDTH="12%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">2,792&nbsp;</font></div>
    </td>
    <td VALIGN=bottom WIDTH="13%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">2,967&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="17">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Advertising and
        product promotion</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">302&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">356</font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,103&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,239&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="17">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Research and development</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">496&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">479</font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,499&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,375&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="51%" height="17">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Provision for restructuring/other
        (See Note 4) </font></dir>
    </td>
    <td valign=bottom width="11%" height="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">240</font></div>
    </td>
    <td valign=bottom width="13%" height="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">386</font></div>
    </td>
    <td valign=bottom width="12%" height="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">240</font></div>
    </td>
    <td valign=bottom width="13%" height="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">508</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="17">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Gain on sales of
        businesses (See Note 4)</font></dir>
    </td>
    <td VALIGN=bottom WIDTH="11%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>(240)&nbsp;</u></font></div>
    </td>
    <td VALIGN=bottom WIDTH="13%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>-&nbsp;</u></font></div>
    </td>
    <td VALIGN=bottom WIDTH="12%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>(317)&nbsp;</u></font></div>
    </td>
    <td VALIGN=bottom WIDTH="13%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>(160)</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="18">&nbsp;</td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="18">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">3,068&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="18">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">3,422</font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="18">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">9,278&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="18">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">9,400&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=bottom WIDTH="51%" HEIGHT="29"><font face="Arial, Helvetica, sans-serif" size="+0">Earnings
      from Continuing Operations Before Income Taxes</font></td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="29">
      <div align="right"><font face="Arial, Helvetica, sans-serif">______ </font></div>
      <p align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,675&nbsp;</font>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="29">
      <div align="right"><font face="Arial, Helvetica, sans-serif">______ </font></div>
      <p align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,141</font>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="29">
      <div align="right"><font face="Arial, Helvetica, sans-serif">______ </font></div>
      <p align="right"><font face="Arial, Helvetica, sans-serif" size="+0">4,863&nbsp;</font>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="29">
      <div align="right"><font face="Arial, Helvetica, sans-serif">______ </font></div>
      <p align="right"><font face="Arial, Helvetica, sans-serif" size="+0">4,032&nbsp;</font>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="24">&nbsp;</td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="24">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="24">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="24">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="24">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="12"><font face="Arial, Helvetica, sans-serif" size="+0">Provision
      for income taxes</font></td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="12">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>444&nbsp;</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="12">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>248</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="12">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>1,287&nbsp;</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="12">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>1,005&nbsp;</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="15">&nbsp;</td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="15">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="15">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="15">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="15">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="16"><font face="Arial, Helvetica, sans-serif" size="+0">Earnings
      from Continuing Operations</font></td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="16">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,231&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">893</font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="16">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">3,576&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">3,027&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="8">&nbsp;</td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="8">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="8">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="8">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="8">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="18"><font face="Arial, Helvetica, sans-serif" size="+0">Discontinued
      Operations</font></td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="18">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="18">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="18">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="18">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="21">
      <blockquote>
        <p><font face="Arial, Helvetica, sans-serif" size="+0"> Net earnings</font></p>
      </blockquote>
    </td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="21">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">14&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="21">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">103</font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="21">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">206&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="21">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">281&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="18">
      <blockquote>
        <p><font face="Arial, Helvetica, sans-serif" size="+0">Net gain on disposal</font></p>
      </blockquote>
    </td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="18">
      <div align="right"><font face="Arial, Helvetica, sans-serif"><u><font size="+0">-</font></u><br>
        &nbsp; <br>
        &nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="18">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>240</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="18">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>-</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="18">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>240</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="17">&nbsp;</td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>14</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>343</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>206</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="17">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>521</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="37"><font face="Arial, Helvetica, sans-serif" size="+0">Net
      Earnings</font></td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="37">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>$1,245</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="37">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>$1,236</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="37">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>$3,782</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="37">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>$3,548</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="30"><font face="Arial, Helvetica, sans-serif" size="+0"><b>Earnings
      Per Common Share</b></font></td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="30">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="30">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="30">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="30">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="8">&nbsp;</td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="8">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="8">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="8">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="8">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="16"><font face="Arial, Helvetica, sans-serif" size="+0">Basic</font></td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="16">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="16">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="16"><font face="Arial, Helvetica, sans-serif" size="+0">Earnings
      from Continuing Operations</font></td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">$.64&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">$.45</font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">$1.84&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">$1.53&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="16">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Discontinued Operations</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="16" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="16" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="17">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Net earnings</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="17" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">-&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="17" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">.05</font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="17" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">.11&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="17" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">.14&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="17">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Net gain on disposal</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="17" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>-</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="17" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>.13</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="17" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>-</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="17" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>.13</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="12">&nbsp;</td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="12" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>-&nbsp;</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="12" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>.18</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="12" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>.11&nbsp;</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="12" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>.27&nbsp;</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="8">&nbsp;</td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="8" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="8" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="8" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="8" align="right">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="18">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Net Earnings</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="18" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>$.64</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="18" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>$.63</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="18" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>$1.95</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="18" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>$1.80</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="8">&nbsp;</td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="8" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="8" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="8" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="8" align="right">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="16"><font face="Arial, Helvetica, sans-serif" size="+0">Diluted</font></td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="16" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="16" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="16">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Earnings from Continuing
        Operations</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">$.63</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">$.45</font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">$1.82&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">$1.51&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="16">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Discontinued Operations</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="16" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="16" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="16">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Net earnings</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">-</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">.05</font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">.10&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">.14&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="16">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Net gain on disposal</font></dir>
    </td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>-</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>.12</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>-</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>.12</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="17">&nbsp;</td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="17" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>-&nbsp;</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="17" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>.17</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="17" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>.10</u></font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="17" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>.26</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="8">&nbsp;</td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="8" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="8" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="8" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="8" align="right">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="18">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Net earnings</font></dir>
    </td>
    <td VALIGN=bottom WIDTH="11%" HEIGHT="18" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>$.63</u></font></div>
    </td>
    <td VALIGN=bottom WIDTH="13%" HEIGHT="18" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>$.62</u></font></div>
    </td>
    <td VALIGN=bottom WIDTH="12%" HEIGHT="18" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>$1.92</u></font></div>
    </td>
    <td VALIGN=bottom WIDTH="13%" HEIGHT="18" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0"><u>$1.77</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="8">&nbsp;</td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="8" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="8" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="8" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="8" align="right">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="16"><font face="Arial, Helvetica, sans-serif" size="+0">Average
      Common Shares Outstanding</font></td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="16" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="16"><font face="Arial, Helvetica, sans-serif" size="+0">Basic</font></td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,936</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,963</font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,941&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,969&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="16"><font face="Arial, Helvetica, sans-serif" size="+0">Diluted</font></td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,960</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,991</font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1,967&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">2,000&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="8">&nbsp;</td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="8" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="8" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="8" align="right">&nbsp; </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="8" align="right">&nbsp; </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="51%" HEIGHT="16"><font face="Arial, Helvetica, sans-serif" size="+0">Dividends
      per common share</font></td>
    <td VALIGN=TOP WIDTH="11%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">$.275</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">$.245</font></div>
    </td>
    <td VALIGN=TOP WIDTH="12%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">$.825&nbsp;</font></div>
    </td>
    <td VALIGN=TOP WIDTH="13%" HEIGHT="16" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">$.735&nbsp;</font></div>
    </td>
  </tr>
</table>





<hr>
<table border=0 cellspacing=0 cellpadding=0 width="685" >
  <tr bgcolor="#FFFFFF" bordercolor="#FFFFFF">
    <td valign=TOP colspan="3" height="16"><a name="_Toc514233764"></a><a name="_Toc514233764"></a><a name="_Toc514233764"></a><a name="_Toc514233764"></a><a name="_Toc514233764"></a><a name="_Toc514474295"></a>
      <center>
        <b><font face="CG Times" size="+1">BRISTOL-MYERS SQUIBB COMPANY</font></b>
      </center>
    </td>
  </tr>
  <tr bgcolor="#FFFFFF" bordercolor="#FFFFFF">
    <td valign=TOP colspan="3" height="16"><a name="_Toc514233764"></a><a name="_Toc514233764"></a><a name="_Toc514233764"></a><a name="_Toc514233764"></a><a name="_Toc514233764"></a><a name="_Toc514474295"></a>
      <center>
        <b><font face="CG Times" size="+1">CONSOLIDATED STATEMENT OF EARNINGS</font></b>
      </center>
    </td>
  </tr>
  <tr bgcolor="#FFFFFF" bordercolor="#FFFFFF">
    <td valign=TOP colspan="3" height="16">
      <center>
        <a name="_Toc514233765"></a><a name="_Toc514233765"></a><a name="_Toc514233765"></a><a name="_Toc514234389"></a><a name="_Toc514474296"></a><b><font face="CG Times" size="+1">AND
        COMPREHENSIVE INCOME</font></b> - <b>continued</b>
      </center>
    </td>
  </tr>
  <tr bgcolor="#FFFFFF" bordercolor="#FFFFFF">
    <td valign=TOP colspan="3" height="16">
      <center>
        <b><font face="CG Times">(Unaudited, in millions except per share amounts)</font></b>
      </center>
    </td>
  </tr>
</table>
<p>&nbsp;</p>
<table border=0 cellspacing=1 cellpadding=0 width="684" >
  <tr>
    <td valign=TOP width="51%"><font face="Arial, Helvetica, sans-serif">Net Earnings</font></td>
    <td valign=TOP width="11%" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif">$1,245</font></div>
    </td>
    <td valign=TOP width="13%" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif">$1,236</font></div>
    </td>
    <td valign=TOP width="12%" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif">$3,782</font></div>
    </td>
    <td valign=TOP width="13%" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif">$3,548</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="51%"><font face="Arial, Helvetica, sans-serif" size="+0">Other
      Comprehensive Income</font></td>
    <td valign=TOP width="11%">&nbsp; </td>
    <td valign=TOP width="13%">&nbsp; </td>
    <td valign=TOP width="12%">&nbsp; </td>
    <td valign=TOP width="13%">&nbsp; </td>
  </tr>
  <tr valign="bottom">
    <td width="51%" height="103">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Foreign currency
        translation, net of taxes of $52 and $(2) for the three months ended September
        30, 2001 and 2000 and $20 and $(4) for the nine months ended September
        30, 2001 and 2000</font></dir>
    </td>
    <td width="11%" height="103">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">1</font></div>
    </td>
    <td width="13%" height="103">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">(4)</font></div>
    </td>
    <td width="12%" height="103">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">31</font></div>
    </td>
    <td width="13%" height="103">
      <div align="right"><font face="Arial, Helvetica, sans-serif" size="+0">(166)</font></div>
    </td>
  </tr>
  <tr valign="bottom">
    <td width="51%">
      <dir><font face="Arial, Helvetica, sans-serif" size="+0">Deferred losses
        on derivatives qualifying as hedges, net of taxes of $(49) and $(30) for
        the three and nine months ended September 30, 2001, respectively</font></dir>
    </td>
    <td width="11%">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif" size="+0">(81)</font></u></div>
    </td>
    <td width="13%">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif" size="+0">-</font></u></div>
    </td>
    <td width="12%">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif" size="+0">(55)</font></u></div>
    </td>
    <td width="13%">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif" size="+0">-</font></u></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="51%">&nbsp;</td>
    <td valign=bottom width="11%">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif" size="+0">(80)</font></u></div>
    </td>
    <td valign=bottom width="13%">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif" size="+0">(4)</font></u></div>
    </td>
    <td valign=bottom width="12%">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif" size="+0">(24)</font></u></div>
    </td>
    <td valign=bottom width="13%">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif" size="+0">(166)</font></u></div>
    </td>
  </tr>
  <tr>
    <td valign=middle width="51%" align="left"><font face="Arial, Helvetica, sans-serif" size="+0">Comprehensive
      Income</font></td>
    <td valign=middle width="11%">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif" size="+0">$1,165</font></u></div>
    </td>
    <td valign=middle width="13%">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif" size="+0">$1,232</font></u></div>
    </td>
    <td valign=middle width="12%">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif" size="+0">$3,758</font></u></div>
    </td>
    <td valign=middle width="13%">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif" size="+0">$3,382</font></u></div>
    </td>
  </tr>
</table>
<p>&nbsp;</p>
  <p><font face="CG Times" size="+0">The accompanying notes are an integral part
    of these financial statements.</font> <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; </p>
  <p>&nbsp; </p>
  <hr>
<table BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="723" 2 >
  <tr BGCOLOR="#FFFFFF">
    <td VALIGN=TOP COLSPAN="4" HEIGHT="16" BGCOLOR="#FFFFFF">
      <center>
        <b><font face="CG Times" size="+1">BRISTOL-MYERS SQUIBB COMPANY</font></b>
      </center>
    </td>
  </tr>
  <tr BGCOLOR="#FFFFFF">
    <td VALIGN=TOP COLSPAN="4" HEIGHT="16" BGCOLOR="#FFFFFF">
      <center>
        <a NAME="_Toc514233766"></a>
      </center>
      <a NAME="_Toc514233766"></a><a NAME="_Toc514233766"></a><a NAME="_Toc514233766"></a><a NAME="_Toc514233766"></a><a NAME="_Toc514233766"></a><a NAME="_Toc514233766"></a><a NAME="_Toc514233766"></a><a NAME="_Toc514233766"></a><a NAME="_Toc514233766"></a><a name="_Toc514474297"></a>
      <center>
        <b><font face="CG Times" size="+1">CONSOLIDATED STATEMENT OF CASH FLOWS</font></b>
      </center>
    </td>
  </tr>
  <tr BGCOLOR="#FFFFFF">
    <td VALIGN=TOP COLSPAN="4" HEIGHT="16" BGCOLOR="#FFFFFF">
      <center>
        <b><font face="CG Times" size="+0">(Unaudited, dollars in millions)</font></b>
      </center>
    </td>
  </tr>
</table>
<table BORDER=0 CELLSPACING=0 CELLPADDING=0 width="697" >
  <tr>
    <td VALIGN=TOP width="474">&nbsp;</td>
    <td VALIGN=TOP COLSPAN="2" align="center">
      <p><font face="Arial, Helvetica, sans-serif">Nine Months</font></p>
      <p><font face="Arial, Helvetica, sans-serif"><u>Ended September 30,</u></font></p>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">&nbsp;</td>
    <td width="122">
      <dir> <font face="Arial, Helvetica, sans-serif"><u>2001</u></font></dir>

    </td>
    <td width="101">
      <dir> <font face="Arial, Helvetica, sans-serif"><u>2000</u></font></dir>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474"><font face="Arial, Helvetica, sans-serif">Cash
      Flows From Operating Activities:</font></td>
    <td VALIGN=TOP width="122">&nbsp;</td>
    <td VALIGN=TOP width="101">&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Net earnings</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">$3,782</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">$3,548</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Depreciation and amortization</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">533</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">560</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Provision for restructuring/other</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">240</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">542</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Gain from sale of businesses/product
        divestitures&nbsp;</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">(317)</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">(562)</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Receivables</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">(387)</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">(636)</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Inventories</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">(116)</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">137</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Accounts payable and accrued
        expenses</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">(484)</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">(183)</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Income taxes</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">350</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">(2)</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Product liability</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">(128)</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">(133)</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Insurance recoverable</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">163</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">80</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Pension contribution</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">(215)</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">(230)</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Other assets and liabilities</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>15</u></font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>(289)</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474"><font face="Arial, Helvetica, sans-serif">Net Cash
      Provided by Operating Activities</font></td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>3,436</u></font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>2,832</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474"><font face="Arial, Helvetica, sans-serif">Cash
      Flows From Investing Activities:</font></td>
    <td VALIGN=TOP width="122">&nbsp;</td>
    <td VALIGN=TOP width="101">&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Proceeds from sales of time
        deposits and marketable securities</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">1,030</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">36</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Purchases of time deposits
        and marketable securities</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">(1,120)</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">-</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Additions to fixed assets</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">(687)</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">(331)</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Proceeds from sale of businesses/product
        divestitures</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">447</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">848</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Purchases of businesses</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">(298)</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">(149)</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Cash held for acquisition
        of DuPont Pharmaceuticals long-term assets</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">(7,156)</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">-</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Other, net</font></dir></td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>(151)&nbsp;</u></font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>(53</u>)&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474"><font face="Arial, Helvetica, sans-serif">Net Cash
      (Used in) Provided by Investing Activities</font></td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>(7,935)</u></font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>351&nbsp;</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474"><font face="Arial, Helvetica, sans-serif">Cash
      Flows From Financing Activities:</font></td>
    <td VALIGN=TOP width="122">&nbsp;</td>
    <td VALIGN=TOP width="101">&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Short-term borrowings</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">1,976</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">(240)</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Proceed from long-term debt</font></dir>
    </td>
    <td valign=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">4,853</font></div>
    </td>
    <td valign=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">2</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Repayments of long-term debt</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">(2)</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">(10)</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Issuances of common stock
        under stock plans</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">202</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">201</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Purchases of treasury stock</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">(1,320)</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">(1,614)</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474">
      <dir><font face="Arial, Helvetica, sans-serif">Dividends paid</font></dir>
    </td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>(1,604)</u></font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>(1,450)&nbsp;</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474"><font face="Arial, Helvetica, sans-serif">Net Cash
      Provided by (Used in) Financing Activities</font></td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>4,105</u></font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>(3,111)&nbsp;</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474"><font face="Arial, Helvetica, sans-serif">Effect
      of Exchange Rates on Cash</font></td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>13&nbsp;</u></font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>(32</u>)</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474"><font face="Arial, Helvetica, sans-serif">(Decrease)/Increase
      in Cash and Cash Equivalents</font></td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif">(381)</font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif">40</font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474"><font face="Arial, Helvetica, sans-serif">Cash
      and Cash Equivalents at Beginning of Period</font></td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>3,182&nbsp;</u></font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>2,720</u></font></div>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP width="474"><font face="Arial, Helvetica, sans-serif">Cash
      and Cash Equivalents at End of Period</font></td>
    <td VALIGN=TOP width="122">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>$2,801</u></font></div>
    </td>
    <td VALIGN=TOP width="101">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>$2,760</u></font></div>
    </td>
  </tr>
</table>
<blockquote>
  <p><font face="CG Times" size="+0">The accompanying notes are an integral part
    of these financial statements.</font> <br>
    &nbsp; <br>
    &nbsp; </p>
  <p>&nbsp; </p>
  <hr>
  <p>
    <center>
      <table border=0 cellspacing=0 cellpadding=0 width="723" 2 >
        <tr bgcolor="#FFFFFF">

        <td valign=TOP colspan="4" height="16" bgcolor="#FFFFFF"> <b><font face="CG Times" size="+1">BRISTOL-MYERS
          SQUIBB COMPANY</font></b> </td>
        </tr>
        <tr bgcolor="#FFFFFF">

        <td valign=TOP colspan="4" height="35" bgcolor="#FFFFFF">
          <p> <font face="CG Times" size="+1"><a name="_Toc514474298"></a>NOTES
            TO CONSOLIDATED FINANCIAL STATEMENTS</font> </p>
          <p>

        </td>
        </tr>
        <tr bgcolor="#FFFFFF">

        <td valign=TOP colspan="4" height="16" bgcolor="#FFFFFF"> <b><font face="CG Times" size="+0">(Unaudited,
          dollars in millions except per share amounts)</font></b> </td>
        </tr>
      </table>


  </center>
  <p>&nbsp;</p>
  <p><a NAME="_Toc514233767"></a><u><font face="Arial, Helvetica, sans-serif" size="+0">Note
    1: Basis of Presentation</font></u> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">In the opinion of management,
    the accompanying unaudited consolidated financial statements include all adjustments
    (consisting only of normal adjustments) necessary for a fair presentation
    of the financial position of Bristol-Myers Squibb Company (the "Company")
    at September 30, 2001 and December 31, 2000, and the results of operations
    for the three and nine months ended September 30, 2001 and 2000, and cash
    flows for the nine months ended September 30, 2001 and 2000. These consolidated
    financial statements should be read in conjunction with the consolidated financial
    statements and the related notes included in the Company's 2000 Annual Report
    on Form 10-K. PricewaterhouseCoopers LLP, the Company's independent accountants,
    have performed a review of the unaudited consolidated financial statements
    included herein, and their review report thereon accompanies this filing.</font>
  </p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">Note 2: Earnings Per
    Share</font></u> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Basic earnings per common
    share are computed using the weighted average number of shares outstanding
    during the year. Diluted earnings per common share are computed using the
    weighted average number of shares outstanding during the year, plus the incremental
    shares outstanding assuming the exercise of dilutive stock options.</font>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">The computations for
    basic earnings per common share and diluted earnings per common share are
    as follows:</font> <br>
    &nbsp; </p>
</blockquote>
<table border=0 cellspacing=0 cellpadding=0 width="716" >
  <tr>
    <td valign=TOP width="56%">&nbsp;</td>
    <td valign=TOP colspan="2">
      <center>
        <font face="Arial, Helvetica, sans-serif" size="3">Three Months</font>
        <p><font size="3" face="Arial, Helvetica, sans-serif"><u>Ended September
          30,</u> </font>
      </center>
    </td>
    <td valign=TOP colspan="2">
      <center>
        <font face="Arial, Helvetica, sans-serif" size="3">Nine Months</font>
        <p><font size="3" face="Arial, Helvetica, sans-serif"><u>Ended September
          30,</u> </font>
      </center>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
  </tr>
  <tr>
    <td valign=TOP width="56%">&nbsp;</td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>2001</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>2000</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>2001</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>2000</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
  </tr>
  <tr>
    <td valign=TOP width="56%"><font face="Arial, Helvetica, sans-serif">Net Earnings
      from Continuing Operations</font></td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif">$1,231</font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif">$893</font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif">$3,576</font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif">$3,027</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%"><font face="Arial, Helvetica, sans-serif">Discontinued
      Operations</font></td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
  </tr>
  <tr>
    <td valign=TOP width="56%">
      <blockquote>
        <p><font face="Arial, Helvetica, sans-serif">Net Earnings</font></p>
      </blockquote>
    </td>
    <td valign=TOP width="11%">
      <div align="right"><font face="Arial, Helvetica, sans-serif">14</font></div>
    </td>
    <td valign=TOP width="11%">
      <div align="right"><font face="Arial, Helvetica, sans-serif">103</font></div>
    </td>
    <td valign=TOP width="11%">
      <div align="right"><font face="Arial, Helvetica, sans-serif">206</font></div>
    </td>
    <td valign=TOP width="11%">
      <div align="right"><font face="Arial, Helvetica, sans-serif">281</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%">
      <blockquote>
        <p><font face="Arial, Helvetica, sans-serif">Net gain on disposal</font></p>
      </blockquote>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>_____-</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>___240&nbsp;</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>_____-</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>___240</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%">&nbsp;</td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>____14</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>___343</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>__206</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>___521</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%"><font face="Arial, Helvetica, sans-serif">Net Earnings</font></td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>_$1,245</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>_$1,236</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>_$3,782</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>_$3,548</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
  </tr>
  <tr>
    <td valign=TOP width="56%"><font face="Arial, Helvetica, sans-serif">Basic:</font></td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
  </tr>
  <tr>
    <td valign=TOP width="56%"><font face="Arial, Helvetica, sans-serif">Average
      Common Shares Outstanding</font></td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>1,936</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>1,963</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>1,941</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>1,969</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
  </tr>
  <tr>
    <td valign=TOP width="56%"><font face="Arial, Helvetica, sans-serif">Earnings
      from Continuing Operations</font></td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif">$.64</font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif">$.45</font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif">$1.84</font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif">$1.53</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%"><font face="Arial, Helvetica, sans-serif">Discontinued
      Operations</font></td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
  </tr>
  <tr>
    <td valign=TOP width="56%">
      <blockquote>
        <p><font face="Arial, Helvetica, sans-serif">Net Earnings</font></p>
      </blockquote>
    </td>
    <td valign=TOP width="11%">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif">___-</font></u></div>
    </td>
    <td valign=TOP width="11%">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif">_.05</font></u></div>
    </td>
    <td valign=TOP width="11%">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif">_.11</font></u></div>
    </td>
    <td valign=TOP width="11%">
      <div align="right"><u><font face="Arial, Helvetica, sans-serif">___-</font></u></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%">
      <blockquote>
        <p><font face="Arial, Helvetica, sans-serif">Net gain on disposal</font></p>
      </blockquote>
    </td>
    <td valign=TOP width="11%">
      <div align=right><u><font face="Arial, Helvetica, sans-serif">___-</font></u></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><u><font face="Arial, Helvetica, sans-serif">.13</font></u></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><u><font face="Arial, Helvetica, sans-serif">___-</font></u></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><u><font face="Arial, Helvetica, sans-serif">_.13</font></u></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%"><font face="Arial, Helvetica, sans-serif">Net Earnings</font></td>
    <td valign=TOP width="11%">
      <div align=right><u><font face="Arial, Helvetica, sans-serif">$.64</font></u></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><u><font face="Arial, Helvetica, sans-serif">$.63</font></u></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><u><font face="Arial, Helvetica, sans-serif">$1.95</font></u></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><u><font face="Arial, Helvetica, sans-serif">$1.80</font></u></div>
    </td>
  </tr>
</table>
<table border=0 cellspacing=0 cellpadding=0 width="715" >
  <tr>
    <td valign=TOP width="0%">
      <p>&nbsp;</p>
      <p>&nbsp;</p>
      <p><font face="Arial, Helvetica, sans-serif">Diluted:</font></p>
    </td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="12%">&nbsp;</td>
    <td valign=TOP width="10%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
  </tr>
  <tr>
    <td valign=TOP width="56%"><font face="Arial, Helvetica, sans-serif">Average
      Common Shares Outstanding</font></td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif">1,936</font></div>
    </td>
    <td valign=TOP width="12%">
      <div align=right><font face="Arial, Helvetica, sans-serif">1,963</font></div>
    </td>
    <td valign=TOP width="10%">
      <div align=right><font face="Arial, Helvetica, sans-serif">1,941</font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif">1,969</font></div>
    </td>
  </tr>
  <tr>
    <td valign=bottom width="56%">
      <dir><font face="Arial, Helvetica, sans-serif">Incremental Shares Outstanding
        Assuming the Exercise of Dilutive Stock Options</font></dir>
    </td>
    <td valign=bottom width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>__24</u></font></div>
    </td>
    <td valign=bottom width="12%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>__28</u></font></div>
    </td>
    <td valign=bottom width="10%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>__26</u></font></div>
    </td>
    <td valign=bottom width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>__31</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%">&nbsp;</td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>1,960</u></font></div>
    </td>
    <td valign=TOP width="12%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>1,991</u></font></div>
    </td>
    <td valign=TOP width="10%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>1,967</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>2,000</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="12%">&nbsp;</td>
    <td valign=TOP width="10%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
  </tr>
  <tr>
    <td valign=TOP width="56%"><font face="Arial, Helvetica, sans-serif">Earnings
      from Continuing Operations</font></td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif">$.63</font></div>
    </td>
    <td valign=TOP width="12%">
      <div align=right><font face="Arial, Helvetica, sans-serif">$.45</font></div>
    </td>
    <td valign=TOP width="10%">
      <div align=right><font face="Arial, Helvetica, sans-serif">$1.82</font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif">$1.51</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%"><font face="Arial, Helvetica, sans-serif">Discontinued
      Operations</font></td>
    <td valign=TOP width="11%">&nbsp;</td>
    <td valign=TOP width="12%">&nbsp;</td>
    <td valign=TOP width="10%">&nbsp;</td>
    <td valign=TOP width="11%">&nbsp;</td>
  </tr>
  <tr>
    <td valign=TOP width="56%"><font face="Arial, Helvetica, sans-serif">Net earnings</font></td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif">-</font></div>
    </td>
    <td valign=TOP width="12%">
      <div align=right><font face="Arial, Helvetica, sans-serif">.05</font></div>
    </td>
    <td valign=TOP width="10%">
      <div align=right><font face="Arial, Helvetica, sans-serif">.10</font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif">.14</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%"><font face="Arial, Helvetica, sans-serif">Net gain
      on disposal</font></td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>-</u></font></div>
    </td>
    <td valign=TOP width="12%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>.12</u></font></div>
    </td>
    <td valign=TOP width="10%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>-</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>.12</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%">&nbsp;</td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>-</u></font></div></td>
    <td valign=TOP width="12%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>.17</u></font></div>
    </td>
    <td valign=TOP width="10%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>.10</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>.26</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="56%"><font face="Arial, Helvetica, sans-serif">Net Earnings</font></td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>$.63</u></font></div>
    </td>
    <td valign=TOP width="12%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>$.62</u></font></div>
    </td>
    <td valign=TOP width="10%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>$1.92</u></font></div>
    </td>
    <td valign=TOP width="11%">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>$1.77</u></font></div>
    </td>
  </tr>
</table>
<blockquote>
  <p>&nbsp; </p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">Note 3: Discontinued
    Operations</font></u> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">In September 2000, the
    Company announced the planned divestitures of its beauty care business "Clairol"
    and orthopaedic business "Zimmer". Accordingly, the operations of Clairol
    (which includes its Matrix affiliate) and Zimmer have been reported as discontinued
    operations in the accompanying condensed consolidated financial statements.</font>
  </p>
  <p>&nbsp; </p>
  <hr>
  <p><br>
  </p>
  <p>
    <center>
      <table border=0 cellspacing=0 cellpadding=0 width="723" 2 >
        <tr bgcolor="#FFFFFF">
          <td valign=TOP colspan="4" height="16" bgcolor="#FFFFFF"> <b><font face="CG Times" size="+1">BRISTOL-MYERS
            SQUIBB COMPANY</font></b> </td>
        </tr>
        <tr bgcolor="#FFFFFF">
          <td valign=TOP colspan="4" height="35" bgcolor="#FFFFFF">
            <p> <font face="CG Times" size="+1"><a name="_Toc514474298"></a>NOTES
              TO CONSOLIDATED FINANCIAL STATEMENTS</font> </p>
            <p>

          </td>
        </tr>
        <tr bgcolor="#FFFFFF">
          <td valign=TOP colspan="4" height="16" bgcolor="#FFFFFF"> <b><font face="CG Times" size="+0">(Unaudited,
            dollars in millions except per share amounts)</font></b> </td>
        </tr>
      </table>

    </center>
  <p></p>
  <p>&nbsp;</p>
  <p><font face="Arial, Helvetica, sans-serif">The net sales and earnings of discontinued
    operations are as follows:</font> <br>
    &nbsp; </p>
</blockquote>
<table border=0 cellspacing=0 cellpadding=3 width="504" >
  <tr>
    <td valign=TOP colspan="2">&nbsp;</td>
    <td valign=TOP colspan="2">
      <div align="center"><font face="Arial, Helvetica, sans-serif">Three Months
        Ended&nbsp;</font></div>
    </td>
    <td valign=TOP colspan="2">
      <div align="center"><font face="Arial, Helvetica, sans-serif">Nine Months
        Ended&nbsp;</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP colspan="2">&nbsp;</td>
    <td valign=TOP colspan="2">
      <div align="center"><font face="Arial, Helvetica, sans-serif"><u>September
        30,</u></font></div>
    </td>
    <td valign=TOP colspan="2">
      <div align="center"><font face="Arial, Helvetica, sans-serif"><u>September
        30,</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP colspan="2">&nbsp;</td>
    <td valign=TOP width="67">
      <div align=right><font face="Arial, Helvetica, sans-serif" size="+0"><u>2001</u></font></div>
    </td>
    <td valign=TOP width="38">
      <div align=right><font face="Arial, Helvetica, sans-serif" size="+0"><u>2000</u></font></div>
    </td>
    <td valign=TOP width="49">
      <div align=right><font face="Arial, Helvetica, sans-serif" size="+0"><u>2001</u></font></div>
    </td>
    <td valign=TOP width="49">
      <div align=right><font face="Arial, Helvetica, sans-serif" size="+0"><u>2000</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP colspan="2" height="56"><font face="Arial, Helvetica, sans-serif">Net
      Sales</font></td>
    <td valign=TOP width="67" height="56">
      <div align=right>
        <p><font face="Arial, Helvetica, sans-serif"><u>$578</u></font></p>
      </div>
    </td>
    <td valign=TOP width="38" height="56">
      <div align=right>
        <p><font face="Arial, Helvetica, sans-serif"><u>$736</u></font></p>
        <p>&nbsp;</p>
      </div>
    </td>
    <td valign=TOP width="49" height="56">
      <div align=right>
        <p><font face="Arial, Helvetica, sans-serif"><u>$2,108</u></font></p>
        <p>
      </div>
    </td>
    <td valign=TOP width="49" height="56">
      <div align=right>
        <p><font face="Arial, Helvetica, sans-serif"><u>$2,402</u></font></p>
        <p>&nbsp;</p>
      </div>
    </td>
  </tr>
  <tr>
    <td valign=TOP colspan="2"><font face="Arial, Helvetica, sans-serif">Earnings
      before income taxes</font></td>
    <td valign=TOP width="67">
      <div align=right><font face="Arial, Helvetica, sans-serif">109</font></div>
    </td>
    <td valign=TOP width="38">
      <div align=right><font face="Arial, Helvetica, sans-serif">168</font></div>
    </td>
    <td valign=TOP width="49">
      <div align=right><font face="Arial, Helvetica, sans-serif">418</font></div>
    </td>
    <td valign=TOP width="49">
      <div align=right><font face="Arial, Helvetica, sans-serif">454</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP colspan="2"><font face="Arial, Helvetica, sans-serif">Income
      taxes (1)</font></td>
    <td valign=TOP width="67">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>_95</u></font></div>
    </td>
    <td valign=TOP width="38">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>__65</u></font></div>
    </td>
    <td valign=TOP width="49">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>212</u></font></div>
    </td>
    <td valign=TOP width="49">
      <div align=right><font face="Arial, Helvetica, sans-serif"><u>_173</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP colspan="2"><font face="Arial, Helvetica, sans-serif">Net earnings
      from discontinued operations</font></td>
    <td valign=bottom width="67">
      <div align=right>
        <p><font face="Arial, Helvetica, sans-serif"><u>$14</u></font></p>
        <p>
      </div>
    </td>
    <td valign=bottom width="38">
      <div align=right>
        <p><font face="Arial, Helvetica, sans-serif"><u>$103</u></font></p>
        <p>
      </div>
    </td>
    <td valign=bottom width="49">
      <div align=right>
        <p><font face="Arial, Helvetica, sans-serif"><u>$206</u></font></p>
        <p>
      </div>
    </td>
    <td valign=bottom width="49">
      <div align=right>
        <p><font face="Arial, Helvetica, sans-serif"><u>$281</u></font></p>
        <p>
      </div>
    </td>
  </tr>
</table>
<p><br>
  <font face="Arial, Helvetica, sans-serif" size="+0">(1) Provision for income
  taxes in the third quarter 2001 includes an additional $53 tax provision related
  to certain Zimmer international jurisdictions.</font></p>
<p><font face="Arial, Helvetica, sans-serif" size="+0">The consolidated balance
  sheet includes the Clairol business at September 30, 2001 and both the Clairol
  and Zimmer businesses at December 31, 2000. The net assets of discontinued operations
  expected to be disposed at September 30, 2001 and December 31, 2000 were as
  follows:</font> <br>
  &nbsp; </p>
<table border=0 cellspacing=0 cellpadding=3 width="576" >
  <tr>
    <td valign=TOP width="342">&nbsp;</td>
    <td valign=TOP align="left" width="113">
      <div align="left"><font face="Arial, Helvetica, sans-serif">September 30,</font></div>
    </td>
    <td valign=TOP align="left" width="103">
      <div align="left"><font face="Arial, Helvetica, sans-serif">December 31,</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="342">&nbsp;</td>
    <td valign=TOP align="left" width="113">
      <div align="center"><font face="Arial, Helvetica, sans-serif"><u> 2001</u></font></div>
    </td>
    <td valign=TOP align="left" width="103">
      <div align="center"><font face="Arial, Helvetica, sans-serif"><u> 2000</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="342"><font face="Arial, Helvetica, sans-serif">Current
      assets</font></td>
    <td valign=TOP width="113">
      <div align="right"><font face="Arial, Helvetica, sans-serif">$527</font></div>
    </td>
    <td valign=TOP width="103">
      <div align="right"><font face="Arial, Helvetica, sans-serif">$866</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="342"><font face="Arial, Helvetica, sans-serif">Property,
      Plant and Equipment, net</font></td>
    <td valign=TOP width="113">
      <div align="right"><font face="Arial, Helvetica, sans-serif">208</font></div>
    </td>
    <td valign=TOP width="103">
      <div align="right"><font face="Arial, Helvetica, sans-serif">340</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="342"><font face="Arial, Helvetica, sans-serif">Noncurrent
      Assets</font></td>
    <td valign=TOP width="113">
      <div align="right"><font face="Arial, Helvetica, sans-serif">104</font></div>
    </td>
    <td valign=TOP width="103">
      <div align="right"><font face="Arial, Helvetica, sans-serif">276</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP width="342"><font face="Arial, Helvetica, sans-serif">Less:</font></td>
    <td valign=TOP width="113">&nbsp; </td>
    <td valign=TOP width="103">&nbsp; </td>
  </tr>
  <tr>
    <td valign=TOP width="342"><font face="Arial, Helvetica, sans-serif">Liabilities
      (principally current)</font></td>
    <td valign=TOP width="113">
      <div align="right"><font face="Arial, Helvetica, sans-serif"><u>376</u></font></div>
    </td>
    <td valign=TOP width="103">
      <div align="right"><font face="Arial, Helvetica, sans-serif"><u>558</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP height="15" width="342">&nbsp;</td>
    <td valign=TOP height="15" width="113">&nbsp; </td>
    <td valign=TOP height="15" width="103">&nbsp; </td>
  </tr>
  <tr>
    <td valign=TOP width="342"><font face="Arial, Helvetica, sans-serif">Net assets
      of discontinued operations</font></td>
    <td valign=TOP width="113">
      <div align="right"><font face="Arial, Helvetica, sans-serif"><u>$463</u></font></div>
    </td>
    <td valign=TOP width="103">
      <div align="right"><font face="Arial, Helvetica, sans-serif"><u>$924</u></font></div>
    </td>
  </tr>
</table>
<p><font face="Arial, Helvetica, sans-serif" size="+0">The consolidated statement
  of cash flows includes the Clairol and Zimmer businesses. Cash flows from operating
  and investing activities of discontinued operations for the nine months ended
  September 30, 2001 and 2000 were $295 million and $956 million, including $600
  million of proceeds from the sale of Matrix Essentials, respectively.</font>
</p>
<blockquote>
  <p>&nbsp; </p>
  <p>&nbsp;</p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">Note 4: Divestitures
    and Restructuring</font></u> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">On August 6, 2001, the
    Company distributed to its shareholders all the shares of Zimmer Holdings
    in a tax-free spin-off, resulting in a reduction of Stockholders' Equity of
    $203 million. </font></p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">In May 2001, the Company
    announced a definitive agreement to sell Clairol to Procter &amp; Gamble for
    $4.95 billion. The sale is expected to be completed in the fourth quarter
    2001, at which time a gain of approximately $2.5 billion after-taxes will
    be recorded in discontinued operations.</font></p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0"> In the third quarter
    and nine months of 2001, the Company recorded a pre-tax gain of $240 million
    on the sale of three pharmaceutical products (Corzide, Delestrogen and Florinef)
    and the licensing rights to CORGARD* in the U.S. to King Pharmaceuticals.
    At the same time, the Company recorded a pre-tax charge of $240 million of
    which $198 million related to the termination of a contract sales force in
    the U.S. and closure of certain overseas manufacturing facilities, and $42
    million for settlement of a litigation over promotional claims brought by
    a distributor of store brand infant formula against Mead Johnson. The restructuring
    charge consisted of $95 million of contract sales force termination fees,
    $28 million of employee termination benefits for approximately 700 employees,
    $60 million of asset write-downs and $15 million of other expenses. The $138
    million restructuring liability originally recorded in accrued expenses has
    been reduced to $69 million at September 30, 2001. The Company expects to
    substantially complete these restructuring activities by mid-2002. Also for
    the nine months of 2001, the Company recorded a pre-tax gain of $77 million
    on the sale of its Estrace tablets and Apothecon commodity business. </font></p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">In the third quarter
    2000, the Company recorded a pre-tax gain of $402 million ($240 million after
    tax) on the sale of its Matrix subsidiary. This gain is included in gain on
    disposal of discontinued operations. During the third quarter of 2000, the
    Company also recorded a charge of $402 million, of which $386 million is included
    in continuing operations and $16 million is included in earnings from discontinued
    operations. In the first nine months of 2000, the Company recorded a pre-tax
    gain of $562 million, of which $160 million of the gain primarily related
    to the sale of Estrace cream, Ovcon 35, and Ovcon 50 was recorded in continuing
    operations, and $402 million ($240 million after tax) related to the sale
    of Matrix was recorded in net gain on disposal in discontinued operations.
    </font></p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">In the first nine months
    of 2000, the Company also recorded restructuring charges of $542 million,
    of which $508 million is included in continuing operations and $34 million
    is included in discontinued operations. The reserve balance, for these restructuring
    charges, was reduced to $93 million at September 30, 2001 from $247 million
    at December 31, 2000. Restructuring activities include workforce reductions
    and the downsizing and streamlining of operations. These restructuring activities
    are expected to be substantially completed by the end of the year. </font><br>
    &nbsp; <br>
    &nbsp; </p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">Note 5: Financial
    Instruments</font></u> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Effective January 1,
    2001, the Company adopted Statement of Financial Accounting Standard (SFAS)
    No. 133, "Accounting for Derivative Instruments and Hedging Activities," as
    amended, which requires that all derivative instruments be recognized as either
    assets or liabilities on the balance sheet and measured at fair value. The
    adoption of this accounting requirement did not have a material effect on
    the Company's consolidated financial statements. </font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">The Company recorded
    a transition adjustment as of January 1, 2001 of $26 million, net of taxes,
    in other comprehensive income/(loss) to record the hedging instruments at
    their fair value. A reconciliation of current period changes, net of taxes,
    included in other comprehensive income follows: </font> </p>
  <table border=0 cellspacing=0 cellpadding=2 width="441" hspace="5" >
    <tr>
      <td valign=TOP width="83%"><font face="Arial, Helvetica, sans-serif"> Transition
        adjustment as of January 1, 2001, net</font></td>
      <td valign=TOP width="17%">
        <div align="right"><font face="Arial, Helvetica, sans-serif">$26</font></div>
      </td>
    </tr>
    <tr>
      <td valign=TOP width="83%"><font face="Arial, Helvetica, sans-serif">Current
        period decreases in fair value, net&nbsp;</font></td>
      <td valign=TOP width="17%">
        <div align="right"><font face="Arial, Helvetica, sans-serif">(40)</font></div>
      </td>
    </tr>
    <tr>
      <td valign=TOP width="83%"><font face="Arial, Helvetica, sans-serif">Recognized
        in earnings, net</font></td>
      <td valign=TOP width="17%">
        <div align="right"><u><font face="Arial, Helvetica, sans-serif">(41)</font></u></div>
      </td>
    </tr>
    <tr>
      <td valign=TOP width="83%" height="21"><font face="Arial, Helvetica, sans-serif">Balance
        at September 30, 2001&nbsp;</font></td>
      <td valign=TOP width="17%">
        <div align="right"><u><font face="Arial, Helvetica, sans-serif">$(55)</font></u></div>
      </td>
    </tr>
  </table>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">The Company is exposed
    to market risk due to changes in currency exchange rates and interest rates.
    As a result, the Company utilizes foreign exchange option and forward contracts
    to offset the effect of exchange rate fluctuations on anticipated foreign
    currency transactions, primarily intercompany inventory purchases expected
    to occur within the next year. For these derivatives, which qualify as hedges
    of future cash flows, the effective portion of changes in fair value is temporarily
    recorded in comprehensive income, then recognized in earnings when the hedged
    item affects earnings. Any ineffective portion of hedges is reported in earnings
    as it occurs. The fair value of derivative instruments, which is recorded
    in prepaid expenses at September 30, 2001, was $68 million.</font> </p>
</blockquote>
<blockquote>
  <p><font face="Arial, Helvetica, sans-serif" size="+0"> To manage interest rate
    risk, the Company utilizes interest rate swap contracts. The Company will
    enter into interest rate swaps to hedge against the effects of adverse changes
    in interest rates on consolidated results of operations and future cash outflows
    for interest. These interest rate swap contracts allow the Company to establish
    a fixed interest rate on anticipated debt issuances. Gains and losses from
    changes in fair value on interest rate swap contracts designated as cash flow
    hedges are initially deferred and recorded in other comprehensive income.
    Amounts are transferred from other comprehensive income and recognized in
    earnings as interest expense in the same period that the hedged item is recognized
    in earnings. </font> </p>
  <p><font face="Arial, Helvetica, sans-serif">In the third quarter and nine months
    of 2001, the Company entered into interest rate hedge contracts, with a notional
    amount of $1 billion and $2 billion, respectively, to manage its exposure
    to changes in interest rates for long-term fixed rate debt issues in connection
    with the DuPont Pharmaceuticals business and ImClone transactions (see Note
    7). The contracts were designated as hedges of the variability of the cash
    flows due to changes in the long-term benchmark interest rates. In the third
    quarter 2001, the Company settled all existing interest rate hedge contracts,
    with a notional amount of $2 billion, which coincided with the issuance of
    the long-term fixed-rate debt. The Company recorded the contract settlements
    at fair value, resulting in a $69 million deferred loss, net of taxes, in
    accumulated other comprehensive income/(loss), which will be recognized as
    a yield adjustment over the terms of the related borrowings.</font></p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">In June 2001, the FASB
    approved issuance of an interpretation of Statement of Financial Accounting
    Standard (SFAS) 133, Derivatives Implementation Group Issue G-20, that will
    allow buyers of options to include the time value of the option in the assessment
    of hedge effectiveness when hedging forecasted cash flows. As a result, in
    the third quarter 2001, the Company deferred $10 million, net of taxes, related
    to the change in time value in other comprehensive income/(loss). </font><br>
    &nbsp; </p>
  <p><u><font face="Arial, Helvetica, sans-serif">Note 6: Pension Contribution</font></u>
  </p>
  <p><font face="Arial, Helvetica, sans-serif">In January 2001, the Company made
    a contribution of $215 million to fund its U.S. Retirement Income Plan.</font>
  </p>
  <p>&nbsp;</p>
  <p><font face="Arial, Helvetica, sans-serif"><u>Note 7: Debt</u></font> </p>
  <p><font face="Arial, Helvetica, sans-serif">In connection with the DuPont Pharmaceuticals
    and ImClone transactions, in September 2001, the company issued $1.5 billion
    of commercial paper and $5 billion of medium-term notes. The notes consist
    of $2.5 billion of 4.75% notes due in 2006 and $2.5 billion of 5.75% notes
    due in 2011. In the nine months of 2001, the company entered into hedge contracts,
    with a notional amount of $2 billion to manage its exposure to changes in
    interest rates on the medium-term notes. In the third quarter of 2001, the
    Company settled all existing interest rate hedge contracts resulting in a
    deferred loss that will be amortized as an adjustment to the yield of the
    notes.</font> <font face="Arial, Helvetica, sans-serif">The effective rates
    for the 2006 and 2011 notes are 5.4% and 6.27%, respectively. </font></p>
  <p></p>
  <p><font face="Arial, Helvetica, sans-serif"><u>Note 8: Subsequent Events</u></font>
  </p>
  <p><font face="Arial, Helvetica, sans-serif">In November 2001, the Company purchased
    14,392,003 shares of ImClone Systems Incorporated, at $70 per share, which
    represented approximately 19.9% of the ImClone shares outstanding just prior
    to the commencement of the offer. This transaction will be accounted for as
    an equity investment in the fourth quarter of 2001. The completion of the
    tender offer is part of a strategic agreement between the Company and ImClone
    to co-develop and co-promote an investigational cancer drug (ERBITUX) for
    a series of payments totaling $1 billion and to acquire an equity stake in
    ImClone for an additional $1 billion. </font> </p>
  <p><font face="Arial, Helvetica, sans-serif">These transactions will be recorded
    in the fourth quarter 2001 and will result in a pre-tax charge of approximately
    $1 billion for the write-off of in-process research and development. In addition,
    the preliminary purchase price allocation will result in approximately $400
    - $450 million of goodwill that will no longer be amortized but instead will
    be reviewed for impairment in accordance with Statement of Financial Accounting
    Standards (SFAS) No. 142. and intangible assets that will be amortized over
    their useful lives. </font></p>
  <p><font face="Arial, Helvetica, sans-serif">In October 2001, the Company completed
    its acquisition of the DuPont Pharmaceuticals business, a wholly owned subsidiary
    of E.I. du Pont de Nemours and Company for $7.8 billion. DuPont Pharmaceuticals
    is primarily a domestic business focused on research, development and delivery
    of pharmaceuticals and imaging</font> <font face="Arial, Helvetica, sans-serif">products.
    This acquisition was financed with the proceeds from the issuance of $1.5
    billion of commercial paper, issuance of $5 billion of medium-term notes and
    internal cash flow for the balance. At September 30, 2001, $7,156 million
    of cash paid out on October 1, 2001 for the long-term assets of the DuPont
    Pharmaceuticals business was classified as a long-term asset on the consolidated
    balance sheet.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif">This acquisition will be recorded
    in the fourth quarter of 2001 using the purchase method of accounting. Accordingly,
    the purchase price will be allocated to the assets acquired and liabilities
    assumed on the basis of their fair values at the date of acquisition. The
    purchase price allocation has been prepared on a preliminary basis and reasonable
    changes are expected as the valuations of assets and liabilities are completed
    and additional information becomes available. The preliminary purchase price
    allocation will result in a purchase accounting charge before taxes of approximately
    $1.9 billion for the write-off of in-process research and development. In
    addition, this allocation will also result in $2.2 billion of intangible assets
    that will be amortized over their useful lives and $3.8 billion of goodwill,
    which will no longer be amortized but instead will be reviewed for impairment
    in accordance with Statement of Financial Accounting Standards (SFAS) No.
    142. </font> </p>
  <p><font face="Arial, Helvetica, sans-serif">The following unaudited pro forma
    financial information presents results as if the acquisition had occurred
    at the beginning of the respective periods: </font> </p>
  <p>&nbsp; </p>
</blockquote>
<table border=0 cellspacing=0 cellpadding=1 width="442" >
  <tr>
    <td valign=TOP height="5" width="31">&nbsp;</td>
    <td valign=TOP height="5" width="230">&nbsp;</td>
    <td valign=TOP colspan="4" height="5">
      <div align="center"><font face="Arial, Helvetica, sans-serif">Nine Months
        </font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP height="5" width="31">&nbsp;</td>
    <td valign=TOP height="5" width="230">&nbsp;</td>
    <td valign=TOP colspan="4" height="5">
      <div align="center"><font face="Arial, Helvetica, sans-serif"><u>Ended September
        30,</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP height="5" width="31">&nbsp;</td>
    <td valign=TOP height="5" width="230">&nbsp;</td>
    <td valign=TOP colspan="2" height="5">
      <div align="right"><font face="Arial, Helvetica, sans-serif"><u>2001</u></font></div>
    </td>
    <td valign=TOP colspan="2" height="5" width="97">
      <div align="right"><font face="Arial, Helvetica, sans-serif"><u>2000</u></font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP height="5" width="31">&nbsp;</td>
    <td valign=TOP height="5" width="230"><font face="Arial, Helvetica, sans-serif">Net
      Sales</font></td>
    <td valign=TOP colspan="2" height="5" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif">$15,066</font></div>
    </td>
    <td valign=TOP colspan="2" height="5" align="right" width="97">
      <div align="right"><font face="Arial, Helvetica, sans-serif">$14,570</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP height="5" width="31">&nbsp;</td>
    <td valign=TOP height="5" width="230"><font face="Arial, Helvetica, sans-serif">Net
      Income</font></td>
    <td valign=TOP colspan="2" height="5" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif">3,199</font></div>
    </td>
    <td valign=TOP colspan="2" height="5" align="right" width="97">
      <div align="right"><font face="Arial, Helvetica, sans-serif">2,846</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP height="5" width="31">&nbsp;</td>
    <td valign=TOP height="5" width="230"><font face="Arial, Helvetica, sans-serif">Earnings
      Per Share - Basic</font></td>
    <td valign=TOP colspan="2" height="5" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif">$1.65</font></div>
    </td>
    <td valign=TOP colspan="2" height="5" align="right" width="97">
      <div align="right"><font face="Arial, Helvetica, sans-serif">$1.45</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP height="5" width="31">&nbsp;</td>
    <td valign=TOP height="5" width="230"><font face="Arial, Helvetica, sans-serif">Earnings
      Per Share - Diluted</font></td>
    <td valign=TOP colspan="2" height="5" align="right">
      <div align="right"><font face="Arial, Helvetica, sans-serif">$1.63</font></div>
    </td>
    <td valign=TOP colspan="2" height="5" align="right" width="97">
      <div align="right"><font face="Arial, Helvetica, sans-serif"> $1.42</font></div>
    </td>
  </tr>
  <tr>
    <td valign=TOP height="5" width="31">&nbsp;</td>
    <td valign=TOP height="5" width="230">&nbsp;</td>
    <td valign=TOP colspan="2" height="5" align="right">&nbsp;</td>
    <td valign=TOP colspan="2" height="5" align="right" width="97">&nbsp;</td>
  </tr>
</table>
<blockquote>
  <p><font face="Arial, Helvetica, sans-serif">These pro forma results have been
    prepared for comparative purposes only, and include certain adjustments such
    as additional amortization expense as a result of intangibles arising from
    the purchase, and increased interest expense on acquisition debt. The pro
    forma results are not necessarily indicative of the results of operations
    which actually would have resulted had the purchase been in effect at the
    beginning of the respective periods or of future results. </font> </p>
  <p>&nbsp;</p>
  <p>&nbsp; </p>
  <hr>
  <br>
  &nbsp; <br>
  &nbsp; <br>
  <p>
    <center>
      <a NAME="_Toc514233773"></a><a NAME="_Toc514474299"></a><b><font face="CG Times" size="+1">Report
      of Independent Accountants</font></b>
    </center>
  </p>
  <table border=0 cellspacing=0 cellpadding=1 >
    <tr>
      <td valign=TOP>&nbsp;</td>
      <td valign=TOP><font face="Arial, Helvetica, sans-serif">To the Board of
        Directors</font></td>
    </tr>
    <tr>
      <td valign=TOP>&nbsp;</td>
      <td valign=TOP><font face="Arial, Helvetica, sans-serif">and Stockholders
        of </font></td>
    </tr>
    <tr>
      <td valign=TOP>&nbsp;</td>
      <td valign=TOP><font face="Arial, Helvetica, sans-serif">Bristol-Myers Squibb
        Company</font></td>
    </tr>
  </table>
  <p>&nbsp;</p>
  <p><font face="Arial, Helvetica, sans-serif">We have reviewed the accompanying
    consolidated balance sheet of Bristol-Myers Squibb Company and its subsidiaries
    as of September 30, 2001, and the related consolidated statements of earnings
    and comprehensive income for the three-month and nine-month periods ended
    September 30, 2001 and 2000 and the consolidated statement of cash flows for
    the nine-month periods ended September 30, 2001 and 2000. These financial
    statements are the responsibility of the Company's management. </font> </p>
  <p><font face="Arial, Helvetica, sans-serif">We conducted our review in accordance
    with standards established by the American Institute of Certified Public Accountants.
    A review of interim financial information consists principally of applying
    analytical procedures to financial data and making inquiries of persons responsible
    for financial and accounting matters. It is substantially less in scope than
    an audit conducted in accordance with auditing standards generally accepted
    in the United States of America, the objective of which is the expression
    of an opinion regarding the financial statements taken as a whole. Accordingly,
    we do not express such an opinion. </font></p>
  <p><font face="Arial, Helvetica, sans-serif">Based on our review, we are not
    aware of any material modifications that should be made to the accompanying
    consolidated interim financial statements for them to be in conformity with
    accounting principles generally accepted in the United States of America.
    </font></p>
  <p><font face="Arial, Helvetica, sans-serif">We previously audited in accordance
    with auditing standards generally accepted in the United States of America,
    the consolidated balance sheet as of December 31, 2000, and the related consolidated
    statements of earnings, comprehensive income and retained earnings and of
    cash flows for the year then ended (not presented herein), and in our report
    dated January 24, 2001 we expressed an unqualified opinion on those consolidated
    financial statements. In our opinion, the information set forth in the accompanying
    consolidated balance sheet as of December 31, 2000, is fairly stated in all
    material respects in relation to the consolidated balance sheet from which
    it has been derived. </font> <br>
    &nbsp; <br>
    &nbsp; </p>
  <table border=0 cellspacing=0 cellpadding=1 width="332" >
    <tr>
      <td valign=TOP>&nbsp;</td>
      <td valign=TOP><font face="Arial, Helvetica, sans-serif">PricewaterhouseCoopers
        LLP </font></td>
    </tr>
    <tr>
      <td valign=TOP>&nbsp;</td>
      <td valign=TOP><font face="Arial, Helvetica, sans-serif">New York, New York</font></td>
    </tr>
    <tr>
      <td valign=TOP>&nbsp;</td>
      <td valign=TOP><font face="Arial, Helvetica, sans-serif">October 23, 2001,
        except as to the discussion of the ImClone transaction described in the
        first and second paragraphs of Note 8, which is as of November 1, 2001</font></td>
    </tr>
  </table>
  <p><br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; </p>
  <p>&nbsp; </p>
  <hr>
  <p><a NAME="_Toc514234395"></a><a NAME="_Toc514234395"></a><a NAME="_Toc514234395"></a><a NAME="_Toc514234395"></a><a NAME="_Toc514234395"></a><a NAME="_Toc514234395"></a><a NAME="_Toc514234395"></a><a NAME="_Toc514474302"></a><u><font face="Arial, Helvetica, sans-serif" size="+0">Item
    2<a NAME="_Toc514474303"></a> Management's Discussion and Analysis of Financial
    Condition and Results of Operations</font></u> </p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">Third Quarter Results
    of Operations</font></u> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Sales for the third quarter
    of 2001 increased 4% (7% excluding foreign exchange) over the prior year to
    $4,743 million. excluding the impact of generic competition in the U.S. for
    TAXOL* and BUSPAR*, sales would have increased 11% (14% excluding foreign
    exchange). The consolidated sales growth resulted from a 5% increase due to
    volume, a 2% increase due to changes in selling prices and a 3% decrease due
    to foreign exchange rate fluctuations. U.S. sales increased 5% and international
    sales increased 1% (9% excluding foreign exchange).</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Worldwide pharmaceutical
    sales increased 6% (8% excluding foreign exchange). U.S. pharmaceutical sales
    increased 7% and international pharmaceutical sales increased 2% (10% excluding
    foreign exchange).</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">GLUCOPHAGE (metformin),
    is the leading branded oral medication for treatment of non-insulin dependent
    (type 2) diabetes. The entire GLUCOPHAGE franchise continued its strong growth
    rate, with sales increasing 44% to $702 million. GLUCOPHAGE sales increased
    16% to $505 million while sales of GLUCOVANCE, launched in August 2000, and
    GLUCOPHAGE XR, launched in October 2000, were $95 million and $102 million,
    respectively.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Worldwide sales of PRAVACHOL*,
    a cholesterol-lowering agent, increased 26% to $561 million, benefiting from
    the early withdrawal from the market of a competitor product in August 2001.</font>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Sales of PLAVIX, a platelet
    aggregation inhibitor, continued their strong growth, increasing 64% to $384
    million, driven in part by the positive results of the CURE study (Clopidogrel
    in Unstable angina to prevent Recurrent ischemic Events), which were published
    in the New England Journal of Medicine in August 2001. In September 2001,
    the U.S. Food and Drug Administration (FDA) granted a priority review for
    the supplemental New Drug Application the Company filed for PLAVIX based on
    the CURE study, which demonstrated that initiating therapy with clopidogrel
    early, on top of standard therapy including aspirin, and continuing its use
    long-term, significantly reduces the risk of heart attack, stroke and cardiovascular
    death by 20 percent in patients with acute coronary syndrome compared with
    patients who received standard therapy alone.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Sales of AVAPRO, an angiotensin
    II receptor blocker for the treatment of hypertension, increased 37% to $137
    million. In September 2001, the FDA granted a priority review for the supplemental
    New Drug Application filed in the U.S. based on the results of the PRIME study
    (Program for Irbersartan Mortality and Morbidity Evaluations), which demonstrated
    that Avapro protects against the progression of kidney disease in people with
    hypertension and type 2 diabetes. AVAPRO and PLAVIX are cardiovascular products
    that were launched from Bristol-Myers Squibb and Sanofi-Synthelabo.</font>
    <br>
    &nbsp; </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Sales of TAXOL* (paclitaxel),
    the Company's leading anti-cancer agent, decreased 33% to $279 million. International
    sales increased 2% (11% excluding foreign exchange) to $159 million, led by
    strong sales growth in Japan while domestic sales decreased 54% to $120 million,
    due to generic competition.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Sales of TEQUIN*, a quinolone
    antibiotic, increased 54% to $80 million in the quarter.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Sales of VIDEX*, an anti-retroviral
    agent, increased 34% to $67 million due to increased sales of VIDEX EC* enteric-coated
    beadlets, launched in 2000.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Sales of BUSPAR*, an
    anti-anxiety agent, declined 84% to $28 million from $175 million in the same
    period of 2000, due to generic competition.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Sales of Oncology Therapeutics
    Network (OTN), a specialty distributor of anti-cancer medicines and related
    products, increased 34% to $366 million.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">ENFAMIL*, the Company's
    largest-selling infant formula, recorded sales of $189 million, an increase
    of 6% from the prior year.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Sales of ostomy products
    increased 6% (11% excluding foreign exchange) to $112 million while sales
    of modern wound care products increased 5% (10% excluding foreign exchange)
    to $63 million.</font> <br>
    &nbsp; <br>
    &nbsp; </p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">Operating Expenses</font></u>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Total expenses for the
    quarter ended September 30, 2001, excluding non-recurring items, as a percentage
    of sales, improved to 64.7% from 66.5% in 2000 primarily due to cost efficiencies
    and cost effectiveness. </font></p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">In the third quarter
    2001, the Company recorded non-recurring items, including a gain on the sale
    of three pharmaceutical products and the licensing rights to CORGARD*, of
    $240 million before taxes and a pre-tax charge of $240 million for termination
    of a contract sales force in the U.S. and closure of certain overseas manufacturing
    facilities, and for settlement of a litigation against Mead Johnson. In the
    third quarter 2000, the Company recorded a restructuring charge to earnings
    from continuing operations of $386 million before taxes. </font></p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Cost of products sold,
    as a percentage of sales, increased to 28.1% from 26.3% in 2000 due to increased
    sales of lower margin products from OTN and a decline in TAXOL* and BUSPAR*
    sales resulting from generic competition. Marketing, selling, administrative
    and other expenses, as a percentage of sales, declined to 19.8% in the quarter
    from 21.9% in 2000 as a result of cost efficiencies and cost effectiveness
    as well as sales force reductions. Expenditures for advertising and promotion
    in support of new and existing products declined 15% to $302 million from
    $356 million in 2000 due to a reduction in support for TAXOL* and BUSPAR*.
    </font></p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Research and development
    expenditures increased 4% to $496 million from $479 million in 2000. Pharmaceutical
    research and development spending as a percentage of pharmaceutical sales,
    was 12.5%, essentially the same as prior year levels.</font></p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0"> In November 2001, the
    Company and Otsuka Pharmaceutical Co., Ltd. announced that a New Drug Application
    (NDA) was submitted to the U.S. Food and Drug Administration (FDA) for aripiprazole,
    an investigational novel drug for the treatment of schizophrenia. A filing
    to market aripiprazole in Europe, with the European Medicines Evaluation Agency
    (EMEA), is anticipated later this year. Also in November 2001, the FDA approved
    TEQUIN* for short-course (5-day) regimen in the treatment of acute bacterial
    exacerbation of chronic bronchitis. In addition, the Company and ImClone Systems
    Incorporated announced that ImClone completed its Biologics License Application
    (BLA) submission to the FDA for approval of ERBITUX (formerly known as IMC-C225)
    for the treatment of irinotecan-refractory colorectal cancer. Bristol-Myers
    Squibb and ImClone have entered into an agreement to co-develop and co-promote
    ERBITUX in the U.S., Canada and Japan. </font></p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">Earnings</font></u>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Earnings before income
    taxes, as reported, were $1,675 compared to $1,141 million in 2000. Net earnings
    increased to $1,231 million from $893 million in 2000 and diluted earnings
    per share increased to $.63 from $.45. Excluding the non-recurring items,
    earnings before income taxes increased 10% to $1,675 million from $1,527 million
    in 2000. On this basis, net earnings increased 9% to $1,231 million compared
    with $1,133 million in 2000. Basic earnings per share increased 10% to $.64
    from $.58 in 2000 and diluted earnings per share increased 11% to $.63 from
    $.57 in 2000.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">The effective income
    tax rate on earnings before income taxes was 26.5% compared with 21.7% in
    2000. Excluding the non-recurring items, the effective tax rate on earnings
    before income taxes increased to 26.5% from 25.8% in 2000 as a result of lower
    production of TAXOL* and BUSPAR*.</font> <br>
    &nbsp; <br>
    &nbsp; </p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">Discontinued Operations</font></u>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Clairol sales decreased
    4% (3% excluding foreign exchange) to $462 million. Domestic sales decreased
    3% while international sales decreased 5% (a 3% decrease excluding foreign
    exchange).</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">On August 6, 2001, the
    Company distributed to its shareholders all the shares of Zimmer Holdings
    in a tax-free spin-off.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Net earnings from discontinued
    operations were $14 million compared with $103 million for the third quarter
    of 2000. This decline is primarily the result of an additional tax provision
    of $53 million recorded in the quarter related to certain Zimmer international
    jurisdictions.</font> <br>
    &nbsp; <br>
  </p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">Nine Months Results
    of Operations</font></u> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Sales for the first nine
    months of 2001 increased 5% (8% excluding foreign exchange) over the prior
    year to $14,141 million. Excluding the impace of generic competition in the
    U.S. TAXOL* and BUSPAR* sales would have increased 10% (13% excluding foreign
    exchange). The consolidated sales growth resulted from a 6% increase due to
    volume, a 2% increase due to changes in selling prices, and a 3% decrease
    due to foreign exchange rate fluctuations. U.S. sales increased 8% and international
    sales remained at prior year levels (a 7% increase excluding foreign exchange).</font>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Worldwide pharmaceutical
    sales increased 7% (10% excluding foreign exchange). U.S. pharmaceutical sales
    increased 10% and international pharmaceutical sales remained at prior year
    levels (a 7% increase excluding foreign exchange).</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">The entire GLUCOPHAGE
    franchise continued its strong growth rate, with sales increasing 44% to $2,022
    million. GLUCOPHAGE sales increased 14% to $1,541 million while GLUCOVANCE,
    launched in August 2000, and GLUCOPHAGE XR, launched in October 2000, had
    sales of $255 million and $226 million, respectively.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Worldwide sales of PRAVACHOL*
    increased 15% (19% excluding foreign exchange) to $1,516 million. Sales of
    PLAVIX increased 52% to $999 million. Sales of TAXOL* (paclitaxel) decreased
    23% to $934 million. International sales increased 6% (15% excluding foreign
    exchange) to $476 million while domestic sales decreased 40% to $458 million,
    due to generic competition. Sales of PARAPLATIN* increased 10% to $530 million.
    Sales of AVAPRO increased 29% to $359 million. Sales of TEQUIN* were $208
    million compared with $89 million in the same period of 2000. Sales of VIDEX*,
    an anti-retroviral agent, increased 35% to $195 million due to increased sales
    of VIDEX EC* enteric-coated beadlets launched in 2000.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Sales of Oncology Therapeutics
    Network (OTN) were $1,044 million, an increase of 35% over the prior year.</font>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">ENFAMIL*, the Company's
    largest-selling infant formula, recorded sales of $572 million, an increase
    of 5% from the prior year.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Sales of ostomy products
    increased 5% (11% excluding foreign exchange) to $330 million while sales
    of modern wound care products increased 6% (12% excluding foreign exchange)
    to $184 million.</font> </p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">Operating Expenses</font></u>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">In the first nine months
    of 2001, the Company recorded non-recurring items, including a gain on the
    sale of three pharmaceutical products and the licensing rights to CORGARD*,
    of $240 million before taxes and a pre-tax charge of $240 million for termination
    of a contract sales force in the U.S. and closure of certain overseas manufacturing
    facilities, and for settlement of litigation against Mead Johnson. In the
    first nine months of 2000, the Company recorded restructuring charges of $508
    million before taxes. The Company also recorded a pre-tax gain on sale of
    businesses of $160 million.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Total expenses for the
    nine months ended September 30, 2001, as a percentage of sales, excluding
    the non-recurring items, improved to 65.6% from 67.4% in 2000 primarily due
    to cost efficiencies and cost effectiveness. </font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Cost of products sold,
    as a percentage of sales, increased to 28.0% from 25.8% in 2000 due to increased
    sales of lower margin products from OTN and a decline in TAXOL* and BUSPAR*
    sales. Marketing, selling, administrative and other expenses, as a percentage
    of sales, declined to 19.7% in the first nine months of 2001 from 22.1% in
    2000 as a result of productivity, cost efficiencies and cost effectiveness.
    Expenditures for advertising and promotion declined 11% to $1,103 million
    from $1,239 million in 2000 primarily due to reduced spending on, TAXOL* and
    BUSPAR*. Research and development expenditures increased 9% to $1,499 million
    from $1,375 million in 2000 as the Company increased its investment in late
    stage compounds. Pharmaceutical research and development spending increased
    11% over the prior year, and as a percentage of pharmaceutical sales, was
    12.8% in the first nine months of 2001 and 12.5% in the first nine months
    of 2000. </font> </p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">Earnings</font></u>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Earnings before income
    taxes, as reported, were $4,863 million compared with $4,032 million in 2000.
    Excluding the non-recurring items, earnings before income taxes increased
    11% to $4,863 million from $4,380 million in 2000. On this basis, net earnings
    increased 10% to $3,576 million compared with $3,240 million in 2000. Basic
    earnings per share increased 12% to $1.84 from $1.65 in 2000 and diluted earnings
    per share increased 12% to $1.82 from $1.62 in 2000. </font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">The effective income
    tax rate on earnings before income taxes was 26.5% compared with 24.9% in
    2000. Excluding the non-recurring items, the effective tax rate on earnings
    before income taxes increased to 26.5% from 26.0% in 2000, as a result of
    lower production of TAXOL* and BUSPAR*. </font> </p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">Discontinued Operations</font></u>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Clairol sales increased
    1% (2% excluding foreign exchange) to $1,412 million. Domestic sales increased
    2% while international sales decreased 2% (a 2% increase excluding foreign
    exchange).</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Net earnings from discontinued
    operations were $206 million compared with $281 million for the first nine
    months of 2000. In 2001, earnings before income taxes include a pre-tax charge
    of $29 million in costs related to Zimmer as well as an additional $53 million
    tax provision related to certain Zimmer international jurisdictions.</font>
  </p>
  <p>&nbsp;  </p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">Financial Position</font></u>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">The balance sheet at
    September 30, 2001 and the statement of cash flows for the nine months then
    ended reflect the Company's strong financial position. Net Cash Provided by
    Operating Activities increased to $3,436 million in 2001 from $2,832 million
    in 2000. Net assets of discontinued operations of $463 million are included
    in the balance sheet at September 30, 2001.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Short-Term borrowings
    were $1,734 million at September 30, 2001 increasing from $162 million at
    December 31, 2000. This increase is a result of commercial paper issued in
    connection with the DuPont transaction.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Long-Term Debt increased
    to $6,259 million from $1,336 million at December 31, 2000, as a result of
    the financing for the DuPont Pharmaceuticals and ImClone transactions. In
    September 2001, the Company issued $5 billion of debt securities of which
    $2.5 billion mature in 2006, and the remaining $2.5 billion mature in 2011.
    In connection with this financing, Moody's and Standard &amp; Poor's reaffirmed
    the Company's AAA credit rating.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">As a result of the Company's
    investment in manufacturing and research facilities, additions to fixed assets
    for the nine months ended September 30, 2001 increased to $687 million from
    $331 million during the same period of 2000. Internally generated funds continue
    to be the Company's primary source for financing expenditures for new plant
    and equipment.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Cash flows from operating
    and investing activities of Discontinued Operations for the nine months ended
    September 30, 2001 were $295 million.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">During the nine months
    ended September 30, 2001, the Company purchased 24 million shares of its common
    stock at a cost of $1.3 billion. Also, the Company announced a $2 billion
    increase in the amount authorized for the stock repurchase program from $12
    billion to $14 billion.</font> </p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">Recent Accounting
    Pronouncements</font></u> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">In June 2001, the Financial
    Accounting Standards Board (FASB) issued Statement of Financial Accounting
    Standard (SFAS) No. 141 "Business Combinations", No. 142, "Goodwill and Other
    Intangible Assets" effective for fiscal years beginning after December 15,
    2001. SFAS No. 141 requires that companies use the purchase method of accounting
    for all business combinations initiated after June 30, 2001 and addresses
    the initial recognition and measurement of goodwill and other intangible assets
    acquired in a business combination. SFAS No. 142 addresses the initial recognition
    and measurement of intangible assets acquired outside a business combination
    and the recognition and measurement of goodwill and other intangible assets
    subsequent to their acquisition. Under the new rules, goodwill and indefinite-lived
    intangible assets will no longer be amortized but will be subject to annual
    impairment tests in accordance with the statements. Other intangible assets
    will continue to be amortized over their useful lives. The elimination of
    goodwill amortization prior to the DuPont Pharmaceuticals and ImClone transactions
    will not have a material effect on the Company's consolidated financial statements.
    Goodwill associated with the DuPont Pharmaceuticals and ImClone transactions
    and all future business combinations will not be amortized, but instead be
    reviewed for impairment at least annually.</font></p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Also, in June 2001, the
    Financial Accounting Standards Board (FASB) issued Statement of Financial
    Accounting Standards (SFAS) No 143 "Accounting for Asset Retirement Obligations"
    effective for fiscal years beginning after June 15, 2002. SFAS No 143 requires
    that the fair value of a liability for an asset retirement obligation be recognized
    in the period in which it is incurred if a reasonable estimate of fair value
    can be made. The adoption of this accounting requirement will not have a material
    effect on the Company's consolidated financial statements.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">In August 2001, the Financial
    Accounting Standards Board (FASB) issued Statement of Financial Accounting
    Standard (SFAS) No. 144, "Accounting for the Impairment or Disposal of Long-Lived
    Assets", effective for fiscal years beginning after December 15, 2001. SFAS
    No. 144 addresses accounting models for use in determining impairment of long
    lived assets and the appropriate methodology for recording and impairment
    loss. The implementation of this accounting requirement is not expected to
    have a material effect upon adoption on the Company's consolidated financial
    statements.</font> </p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">Forward-Looking Information</font></u>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">This Form 10-Q Quarterly
    Report, and other written and oral statements that the Company makes from
    time to time, contain certain forward-looking statements within the meaning
    of the Private Securities Litigation Reform Act of 1995 regarding, among other
    things, statements relating to goals, plans and projections with respect to
    the Company's financial position, results of operations, market position,
    product development and business strategy. These statements may be identified
    by the fact that they use words such as "anticipate," "estimate," "expect,"
    "project," "intend," "plan," "believe," and other words and terms of similar
    meaning in connection with any discussion of future operating or financial
    performance. Such forward-looking statements are based on current expectations
    and involve inherent risks and uncertainties, including factors that could
    delay, divert or change any of them, and could cause actual outcomes and results
    to differ materially from current expectations. These factors include, among
    other things, market factors, competitive product development, governmental
    regulations and legislation, patent positions and litigation. Certain factors
    that may affect the Company's operations and prospects are discussed in Exhibit
    99 to the Company's Annual Report on Form 10-K for the year ended December
    31, 2000. We undertake no obligation to publicly update any forward-looking
    statement, whether as a result of new information, future events or otherwise.</font>
    <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; </p>
  <p>&nbsp; </p>
  <hr>
  <p><a NAME="_Toc514233777"></a><a NAME="_Toc514233777"></a><a NAME="_Toc514233777"></a><a NAME="_Toc514233777"></a><a NAME="_Toc514474304"></a><b><u><font face="Arial, Helvetica, sans-serif" size="+0">PART
    II - OTHER INFORMATION</font></u></b> </p>
  <p><a NAME="_Toc514233778"></a><a NAME="_Toc514233778"></a><a NAME="_Toc514233778"></a><a NAME="_Toc514233778"></a><a NAME="_Toc514474305"></a><u><font face="Arial, Helvetica, sans-serif" size="+0">Item
    1. Legal Proceedings</font></u> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Various lawsuits, claims
    and proceedings of a nature considered ordinary and routine to its business
    are pending against the Company and certain of its subsidiaries. The most
    significant of these are reported in the Company's Annual Report on Form 10-K
    for the fiscal year ended December 31, 2000 and material developments in such
    matters are described below.</font> </p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">TAXOL* LITIGATION</font></u>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">In 1997 and 1998, the
    Company filed several lawsuits alleging that a number of generic drug companies
    infringed its patents covering methods of administering paclitaxel when they
    filed abbreviated new drug applications seeking regulatory approval to sell
    paclitaxel. These actions were consolidated for discovery in the United States
    District Court for the District of New Jersey ("District Court"). The Company
    did not assert a monetary claim against any of the defendants, but sought
    to prevent the defendants from marketing paclitaxel in a manner that violates
    the Company's patents.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">The defendants asserted
    that they did not infringe the Company's patents and that these patents are
    invalid and unenforceable. Some defendants also asserted counterclaims seeking
    damages for alleged antitrust and unfair competition violations. The Company
    believed its patents were valid when it filed the suits and the counterclaims
    asserted are believed to be without merit. Since the filing of the suits five
    private actions have been filed by parties alleging antitrust, consumer protection
    and similar claims relating to the Company's action to obtain and enforce
    patent rights. The Federal Trade Commission and the Attorney General of the
    State of Florida have each initiated investigations relating to paclitaxel.
    At this time, neither agency has brought any claims against the Company relating
    to paclitaxel, nor have they indicated whether any such claims will be brought.
    The Company is cooperating in these investigations.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">In early 2000 the District
    Court invalidated most claims of the Company's patents. On April 20, 2001,
    the United States Court of Appeals for the Federal Circuit affirmed the District
    Court's summary judgment of invalidity of all but two claims of the patents
    at issue. Those two claims relate to the low dose, three-hour administration
    of paclitaxel in which the patient is given a specified regimen of premedicants
    before the administration of paclitaxel. The appellate court remanded those
    two claims to the District Court for further proceedings.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">In September 2000, one
    of the defendants received final approval from the United States Food and
    Drug Administration for its Abbreviated New Drug Application for paclitaxel
    and is marketing the product. Additional final approvals have since been announced
    by the United States Food and Drug Administration and sales of additional
    generic products have begun. On November 6, 2001, the United States Appeals
    Court for the District of Columbia Circuit,in a case brought by a company
    not affiliated with Bristol-Myers Squibb against the FDA, ruled the FDA approval
    order was "arbitrary and capricious" and directed the lower court to vacate
    it. The Court stated, "We frankly do not know what recourse is left to the
    FDA or other government agencies to take any steps that would affect the marketing
    of generic versions of Taxol."</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">The Company is considering
    its options with respect to the two remaining claims of its patents. It is
    not possible at this time to make a reasonable assessment as to the final
    outcome of these lawsuits and investigations. Nor is it possible to reasonably
    estimate the impact those litigation's and investigations might have if the
    Company were not to prevail.</font> </p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">BUSPAR*</font></u>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">On November 21, 2000,
    the Company obtained a patent, U.S. Patent No. 6,150,365 ( &quot;'365 patent"),
    relating to a method of using BuSpar* or buspirone. The Company timely submitted
    information relating to the '365 patent to the FDA for listing in an FDA publication
    commonly known as the "Orange Book", and the FDA thereafter listed the patent
    in the Orange Book.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Delisting Suits. Generic
    drug manufacturers sued the FDA and the Company to compel the delisting of
    the '365 patent from the Orange Book. Although one district court declined
    to order the delisting of the '365 patent, another ordered the Company to
    cause the delisting of the patent from the Orange Book. The Company complied
    with the court's order but appealed the decision to the United States Court
    of Appeals for the Federal Circuit, which ruled that it was improper for the
    district court to order the Company to delist its patent from the Orange Book.
    It is not possible at this time to predict what impact, if any, this decision
    will have on sales of Buspar*.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Patent Suits. The Company
    is seeking to enforce the '365 patent in actions against two generic drug
    manufacturers.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Antitrust Suits. Following
    the delisting of the '365 patent from the Orange Book, a number of purchasers
    of buspirone and several generic drug makers filed lawsuits against the Company
    alleging that it improperly triggered statutory marketing exclusivity. The
    central issue raised by these cases is whether the Company improperly caused
    the listing of the '365 patent in the Orange Book. Plaintiffs seek declaratory
    judgment, damages, disgorgement and injunctive relief.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Multidistrict Litigation
    (MDL) proceedings. The Judicial Panel on MDL granted the Company's motions
    to have all of the patent and antitrust cases consolidated in a single forum.</font>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Government Investigations.
    The Federal Trade Commission and a number of state attorneys general have
    initiated investigations concerning the listing of the '365 patent in the
    Orange Book. The Company is cooperating in these investigations.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">It is not possible at
    this time to make a reasonable assessment as to the final outcome of these
    lawsuits and investigations. Nor is it possible to reasonably estimate the
    impact these litigations and investigations might have if the Company were
    not to prevail.</font> </p>
  <p><u><font face="Arial, Helvetica, sans-serif" size="+0">Item 6. Exhibits and
    Reports on Form 8-K</font></u> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">a) Exhibits (listed by
    number corresponding to the Exhibit Table of Item 601 in Regulation S-K).</font>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0"><u>Exhibit Number and
    Description</u> <u>Page</u></font> <br>
    &nbsp; </p>
</blockquote>
<table BORDER=0 CELLSPACING=0 CELLPADDING=7 WIDTH="601" >
  <tr>
    <td VALIGN=TOP WIDTH="9%" rowspan="2">&nbsp;</td>
    <td VALIGN=TOP WIDTH="9%" rowspan="2">&nbsp;</td>
    <td VALIGN=TOP WIDTH="9%" rowspan="2"><font face="Arial, Helvetica, sans-serif">15.</font></td>
    <td VALIGN=TOP WIDTH="64%"><font face="Arial, Helvetica, sans-serif">Independent
      Accountants' Awareness Letter.&nbsp;</font></td>
    <td VALIGN=TOP WIDTH="27%"><font face="Arial, Helvetica, sans-serif">E-15-1</font></td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="64%"></td>
    <td VALIGN=TOP WIDTH="27%"></td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="9%"></td>
    <td VALIGN=TOP WIDTH="9%"></td>
    <td VALIGN=TOP WIDTH="9%"></td>
    <td VALIGN=TOP WIDTH="64%"></td>
    <td VALIGN=TOP WIDTH="27%"></td>
  </tr>
</table>
<blockquote>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">b) Reports on Form 8-K.</font>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">On October 12, 2001,
    the Company filed a form 8-K announcing the completion of the purchase of
    the DuPont Pharmaceuticals business on October 1, 2001.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">On September 25, 2001,
    a form 8-K was filed by the Company announcing that it expects to re-file
    its New Drug Application (NDA) with the U.S. Food and Drug Administration
    (FDA) for VANLEV *.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">On September 20, 2001,
    as amended on September 25, 2001, the Company filed forms 8-K/A, which included
    the financial statements and pro forma financial information required in connection
    with the anticipated acquisition of the DuPont Pharmaceuticals business.</font>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">On September 19, 2001,
    a form 8-K was filed by the Company announcing that it had reached an agreement
    with ImClone Systems Incorporated to co-develop and co-promote a cancer drug
    in the United States, Canada and Japan and to acquire through tender offer
    approximately 19.9% of the outstanding shares of the Company.</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">&nbsp; * Indicates brand
    names of products which are trademarks owned by the company</font> </p>
  <p>&nbsp;</p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">GLUCOPHAGE, GLUCOPHAGE
    XR and GLUCOVANCE are trademarks owned by</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Lipha SA PLAVIX, AVAPRO
    and CURE are trademarks owned by Sanofi-Synthelabo</font> </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">ERBITUX is a trademark
    owned by ImClone Systems Incorporated</font> <br>
  </p>
  <hr>
</blockquote>
<dir>
  <dir>
    <blockquote>
      <p>&nbsp;</p>
    </blockquote>
  </dir>
</dir>
<blockquote>
  <p>
    <center>
      <a NAME="_Toc514233781"></a><a NAME="_Toc514233781"></a><a NAME="_Toc514233781"></a><a NAME="_Toc514233781"></a><a NAME="_Toc514474308"></a><b><u><font face="Arial, Helvetica, sans-serif" size="+1">SIGNATURES</font></u></b>
    </center>
  </p>
  <p><font face="Arial, Helvetica, sans-serif" size="+0">Pursuant to the requirements
    of the Securities Exchange Act of 1934, the Registrant has duly caused this
    report to be signed on its behalf by the undersigned thereunto duly authorized.</font>
    <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; </p>
</blockquote>
<table BORDER CELLPADDING=7 WIDTH="312" >
  <tr>
    <td VALIGN=TOP HEIGHT="45">
      <center>
        <u><font face="CG Times">BRISTOL-MYERS SQUIBB COMPANY&nbsp;</font></u>
      </center>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP><font face="CG Times">(Registrant)</font></td>
  </tr>
</table>
<blockquote>
  <p><br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; </p>
</blockquote>
<table BORDER CELLPADDING=7 WIDTH="625" >
  <tr>
    <td VALIGN=TOP WIDTH="33%" HEIGHT="45"><font face="CG Times">Date: November
      14, 2001</font></td>
    <td VALIGN=TOP WIDTH="67%" HEIGHT="45"><u><font face="CG Times">By: /s/ Curtis
      L. Tomlin</font></u></td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="33%"></td>
    <td VALIGN=TOP WIDTH="67%"><font face="CG Times">Curtis L. Tomlin</font>
      <p><font face="CG Times">Vice President and Controller</font>
    </td>
  </tr>
</table>
<blockquote>
  <p><br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; </p>
</blockquote>
<table BORDER CELLPADDING=7 WIDTH="625" >
  <tr>
    <td VALIGN=TOP WIDTH="33%" HEIGHT="40"><font face="CG Times">Date: November
      14, 2001</font></td>
    <td VALIGN=TOP WIDTH="67%" HEIGHT="40">
      <center>
        <u><font face="CG Times">By: /s/ Harrison M. Bains, Jr.</font></u>
      </center>
    </td>
  </tr>
  <tr>
    <td VALIGN=TOP WIDTH="33%"></td>
    <td VALIGN=TOP WIDTH="67%"><font face="CG Times">Harrison M. Bains, Jr.</font>
      <p><font face="CG Times">Vice President and Treasurer</font>
    </td>
  </tr>
</table>
<blockquote>
  <p><br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; </p>
</blockquote>
<dir>
  <blockquote>
    <div align=right><font face="CG Times">Exhibit No. 15</font></div>
    <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp; <br>
    &nbsp;
    <p><font face="CG Times">Securities and Exchange Commission</font> </p>
    <p><font face="CG Times">450 Fifth Street, N.W.</font> </p>
    <p><font face="CG Times">Washington, D.C. 20549</font> </p>
    <p><font face="CG Times">Commissioners:</font> </p>
    <p><font face="CG Times">We are aware that our report dated October 23, 2001,
      except as to the discussion of the ImClone transaction described in the
      first and second paragraphs of note 8, which is as of November 1, 2001,
      on our review of interim financial information of Bristol-Myers Squibb Company
      (the "Company") as of and for the period ended September 30, 2001 and included
      in the Company's quarterly report on Form 10-Q for the quarter then ended
      is incorporated by reference in its Registration Statements on Form S-8
      (Nos. 33-30856, 33-38411, 33-38587, 33-44788, 333-47403, 33-52691, 33-30756-02,
      33-58187, 333-02873 and 333-65424), Form S-4 (No. 333-09519) and Form S-3
      (Nos. 33-33682, 33-62496, 333-65444 and 333-49227).</font> </p>
    <p><font face="CG Times">Such report is not a "report" or "part" of a registration
      statement prepared or certified by PricewaterhouseCoopers LLP within the
      meaning of Sections 7 and 11 of the Securities Act of 1933 and the independent
      accountants' liability under Section 11 does not extend to such report.</font>
      <br>
      &nbsp; <br>
      &nbsp; </p>
    <p><font face="CG Times">Very truly yours,</font> <br>
      &nbsp; <br>
      &nbsp; <br>
      &nbsp; <br>
      &nbsp; </p>
    <p><font face="CG Times">PricewaterhouseCoopers LLP</font> </p>
    <p><font face="CG Times">New York, New York</font> </p>
    <p><font face="CG Times">November 14, 2001</font> <br>
      &nbsp; <br>
      &nbsp; <br>
      &nbsp; <br>
      &nbsp;</p>
  </blockquote>
</dir>

</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
